Formulations of Anti-interleukin 1 receptor 1 antibodies

Abstract

The present invention provides, among other things, stable formulations comprising an anti- Interleukin 1 Receptor 1 (IL1R1) antibody at a concentration of greater than 80 mg / ml with a pH ranging from 4.4 – 5.7, wherein the amount of HMW species in the formulation increases less than 2% upon storage at 25° C for at least 4 weeks.

Description

FORMULATIONS OF ANTI-INTERLEUKIN 1 RECEPTOR 1 ANTIBODIESCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to, and the benefit of, U.S. Provisional Application No. 63 / 762,497, filed February 24, 2025, U.S Provisional Application No. 63 / 670,418, filed July 12, 2024, U.S Provisional Application No. 63 / 664,017, filed June 25,2024, and U.S. Provisional Application No. 63 / 663,761, filed June 25, 2024, the disclosure of each of which is hereby incorporated by reference in its entirety.INCORPORATION-BY-REFERENCE OF SEQUENCE LISTING

[0002] The present specification includes a Sequence Listing submitted electronically as an XML file named “KPL-060W01_SL.XML”. The XML file was generated June 25,2025, and is 12,735 bytes in size. The entire contents of the Sequence Listing are incorporated by reference herein.BACKGROUND

[0003] Developments in biotechnology have made it possible to produce a large variety of monoclonal antibodies for pharmaceutical applications. Because antibodies are larger and more complex than traditional organic and inorganic drugs, the formulation of such proteins poses special problems. One of the problems is the elevated viscosity values of antibody formulations, especially at high protein concentrations. Another problem is maintaining stability in antibody formulations, which is a critical concern for regulatory agencies. The delivery of high protein concentration is often required for subcutaneous administration due to volume limitations and dose requirements. Subcutaneous administration is an attractive route of delivery because it is less invasive for patients and reduces inconvenience and discomfort for them. Proteins tend to form viscous solutions at high concentration because of their macromolecular nature and potential for intermolecular interactions.

[0004] Furthermore, each antibody has a unique amino acid sequence and three- dimensional structure, leading to differences in physicochemical properties like isoelectric point, hydrophobicity, and surface charge distributions. The optimal pH, ionic strength, buffer type and excipients required for stabilization vary for each antibody based on its specific structural characteristics. A “one-size-fits-all” formulation is not feasible.SUMMARY OF THE INVENTION

[0005] The present invention provides, among other things, stable formulations comprising an anti-Interleukin 1 Receptor 1 (IL1R1) antibody at a concentration of greater than 80 mg / ml with a pH ranging from 4.4-6.5, wherein the amount of high molecular weight (HMW) species in the formulation increases less than 2% upon storage at 25° C for at least 4 weeks. As described herein, the present invention is, in part, based on a finding that the use of arginine at a concentration of less than about 130 mM stabilizes the formulation such that the amount of HMW species in the formulation increases less than 40% upon storage at a high temperature (e.g., 40° C). It was determined that at certain concentrations arginine can cause destabilization of an IL1R1 antibody. This was surprising as arginine is a frequently used excipient for enhancing protein refolding and reducing aggregation. Arginine is also used to reduce viscosity of high concentration antibody formulations. As such, it is typically desirable to use arginine at a high concentration to prevent aggregation while reducing viscosity of antibody formulations. In fact, several antibody formulations use arginine at a high concentration, such as 31.6 mg / ml Arg-HCl (150 mM) and at 26.1 mg / ml Arg (150 mM) in ADUHELM® and ENSPRYNG® formulations, respectively. The present invention is, in part, based on the identification of anti-ILl-Rl antibody formulations comprising a relatively low concentration of arginine (e.g., < 130 mM) with high stability and low viscosity. In some embodiments, the amount of HMW species in the formulation increases less than 15% upon storage at 40° C for 4 weeks. In some embodiments, the formulation comprises less than 130 mM of arginine.

[0006] In one aspect, the present invention provides, among other things, a stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises less than 130 mM arginine and a pH of 4.4 - 6.5, wherein the anti- IL1R1 antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT), and wherein the anti-ILlRl antibody is present at a concentration of greater than 80 mg / ml.

[0007] In some embodiments, the anti-ILlRl antibody has a pl of 7.4 to 7.8. In some embodiments, the anti-ILlRl antibody has a pl of 7.6.

[0008] In some embodiments, a formulation comprises a buffer.

[0009] In some embodiments, the buffer is present at a concentration of 10 mM to150 mM. In some embodiments, the buffer is present at a concentration of 15 mM to 100 mM. In some embodiments, the buffer is present at a concentration of 15 mM to 75 mM. In some embodiments, the buffer is present at a concentration of 25 mM to 50 mM. In some embodiments, the buffer is present at a concentration of 10 mM. In some embodiments, the buffer is present at a concentration of 15 mM. In some embodiments, the buffer is present at a concentration of 20 mM. In some embodiments, the buffer is present at a concentration of 25 mM. In some embodiments, the buffer is present at a concentration of 10 mM. In some embodiments, the buffer is present at a concentration of 30 mM. In some embodiments, the buffer is present at a concentration of 40 mM. In some embodiments, the buffer is present at a concentration of 50 mM. In some embodiments, the buffer is present at a concentration of 60 mM. In some embodiments, the buffer is present at a concentration of 70 mM. In some embodiments, the buffer is present at a concentration of 75 mM.

[0010] In some embodiments, the buffer comprises acetate, succinate, histidine, or phosphate. In some embodiments, the buffer is acetate. In some embodiments, the buffer is succinate. In some embodiments, the buffer is histidine. In some embodiments, the buffer is phosphate.

[0011] In some embodiments, the concentration of acetate, succinate, histidine, or phosphate is present at a concentration of 10 mM to 150 mM. In some embodiments, the concentration of acetate, succinate, histidine, or phosphate is present at a concentration of 15 mM and 100 mM. In some embodiments, the concentration of acetate, succinate, histidine, or phosphate is present at a concentration of 15 to 75 mM. In some embodiments, the concentration of acetate, succinate, histidine, or phosphate is present at a concentration of 25 mM to 50 mM.

[0012] In some embodiments, the pH of the stable formulation is 4.0 to6.5. In some embodiments, the pH of the stable formulation is 4.4 to 6.5. In some embodiments, the pH of the stable formulation is 4.5 to 6.5. In some embodiments, the pH of the stable formulation is 4.5 to 6.0. In some embodiments, the pH of the stable formulation is 4.4 to 5.7. In some embodiments, the pH of the stable formulation is 4.4 to 5.4. In some embodiments, the pH of the stable formulation is 4.7 to 5.1. In some embodiments, the pH of the stable formulation is 4.7 to 5.7. In some embodiments, the pH of the stable formulation is 5.0 to 5.4. In someembodiments, the pH of the stable formulation is 5.0 to 5.5. In some embodiments, the pH of the stable formulation is 4.5 to 5.5. In some embodiments, the pH of the stable formulation is 5.0 to 6.1. In some embodiments, the pH of the stable formulation is 4.0. In some embodiments, the pH of the stable formulation is 4.1. In some embodiments, the pH of the stable formulation is 4.2. In some embodiments, the pH of the stable formulation is 4.3. In some embodiments, the pH of the stable formulation is 4.4. In some embodiments, the pH of the stable formulation is 4.5. In some embodiments, the pH of the stable formulation is 4.6. In some embodiments, the pH of the stable formulation is 4.7. In some embodiments, the pH of the stable formulation is 4.8. In some embodiments, the pH of the stable formulation is 4.9. In some embodiments, the pH of the stable formulation is 5.0. In some embodiments, the pH of the stable formulation is 5.1. In some embodiments, the pH of the stable formulation is 5.2. In some embodiments, the pH of the stable formulation is 5.3. In some embodiments, the pH of the stable formulation is 5.4. In some embodiments, the pH of the stable formulation is 5.5. In some embodiments, the pH of the stable formulation is 5.6. In some embodiments, the pH of the stable formulation is 5.7. In some embodiments, the pH of the stable formulation is 5.8. In some embodiments, the pH of the stable formulation is 5.9. In some embodiments, the pH of the stable formulation is 6.0. In some embodiments, the pH of the stable formulation is 6.1. In some embodiments, the pH of the stable formulation is 6.2. In some embodiments, the pH of the stable formulation is 6.3. In some embodiments, the pH of the stable formulation is 6.4. In some embodiments, the pH of the stable formulation is 6.5. In some embodiments, the pH of the stable formulation is 6.6. In some embodiments, the pH of the stable formulation is 6.7. In some embodiments, the pH of the stable formulation is 6.8. In some embodiments, the pH of the stable formulation is 6.9. In some embodiments, the pH of the stable formulation is 7.0.

[0013] In some embodiments, the stable formulation comprises arginine, which is present at a concentration of 10 mM to 100 mM. In some embodiments, arginine is present at a concentration of 15 mM to 80 mM. In some embodiments, arginine is present at a concentration of 15 mM to 75 mM. In some embodiments, arginine is present at a concentration of 10 mM to 50 mM. In some embodiments, the formulation comprises less than 130 mM arginine. In some embodiments, the formulation comprises less than 125 mM arginine. In some embodiments, the formulation comprises less than 120 mM arginine. In some embodiments, the formulation comprises less than 115 mM arginine. In some embodiments, the formulation comprises less than 110 mM arginine. In some embodiments,the formulation comprises less than 100 mM arginine. In some embodiments, the formulation comprises less than 90 mM arginine. In some embodiments, the formulation comprises less than 80 mM arginine. In some embodiments, the formulation comprises less than 75 mM arginine. In some embodiments, the formulation comprises less than 70 mM arginine. In some embodiments, the formulation comprises less than 60 mM arginine. In some embodiments, the formulation comprises less than 55 mM arginine. In some embodiments, the formulation comprises less than 50 mM arginine. In some embodiments, the formulation comprises less than 45 mM arginine. In some embodiments, the formulation comprises less than 40 mM arginine. In some embodiments, the formulation comprises less than 35 mM arginine. In some embodiments, the formulation comprises less than 30 mM arginine. In some embodiments, the formulation comprises less than 25 mM arginine. In some embodiments, the formulation comprises less than 20 mM arginine. In some embodiments, the formulation comprises less than 15 mM arginine. In some embodiments, the formulation comprises less than 10 mM arginine. In some embodiments, the formulation is substantially free or arginine. In some embodiments, arginine is not added to a formulation. In some embodiments, arginine is not detectable in a formulation.

[0014] In some embodiments, the formulation comprises 50 mM arginine. In some embodiments, the formulation comprises 55 mM arginine. In some embodiments, the formulation comprises 60 mM arginine. In some embodiments, the formulation comprises 65 mM arginine. In some embodiments, the formulation comprises 66 mM arginine. In some embodiments, the formulation comprises 67 mM arginine. In some embodiments, the formulation comprises 68 mM arginine. In some embodiments, the formulation comprises 69 mM arginine. In some embodiments, the formulation comprises 70 mM arginine. In some embodiments, the formulation comprises 75 mM arginine. In some embodiments, the formulation comprises 80 mM arginine. In some embodiments, the formulation comprises 85 mM arginine. In some embodiments, the formulation comprises 90 mM arginine. In some embodiments, the formulation comprises 95 mM arginine. In some embodiments, the formulation comprises 100 mM arginine.

[0015] In some embodiments, the stable formulation comprises a sugar.

[0016] In some embodiments, the sugar is trehalose. In some embodiments, the sugar is sucrose. In some embodiments, the sugar is lactose. In some embodiments, the sugar is mannitol. In some embodiments, the sugar is mellibose. In some embodiments, the sugar ismelezitose. In some embodiments, the sugar is raffinose. In some embodiments, the sugar is mannotriose. In some embodiments, the sugar is stachyose.

[0017] In some embodiments, the stable formulation comprises a sugar at concentrations of 0-20% (w / v). In some embodiments, the sugar is present at concentrations of 1-15% (w / v). In some embodiments, the sugar is present at concentrations of 2-10% (w / v). In some embodiments, the sugar is present at concentrations of 3-8% (w / v). In some embodiments, the sugar is present at concentrations of 2% (w / v). In some embodiments, the sugar is present at concentrations of 3% (w / v). In some embodiments, the sugar is present at concentrations of 4% (w / v). In some embodiments, the sugar is present at concentrations of 5% (w / v). In some embodiments, the sugar is present at concentrations of 6% (w / v). In some embodiments, the sugar is present at concentrations of 7% (w / v). In some embodiments, the sugar is present at concentrations of 8% (w / v). In some embodiments, the sugar is present at concentrations of 9% (w / v). In some embodiments, the sugar is present at concentrations of 10% (w / v).

[0018] In some embodiments, the stable formulation comprises a surfactant.

[0019] In some embodiments, the surfactant is polysorbate-20. In some embodiments, the surfactant is polysorbate-80.

[0020] In some embodiments, the stable formulation comprises a surfactant, which is present at concentrations of 0% to 0.1% (w / v). In some embodiments, the surfactant is present at concentrations of 0.001% to 0.05% (w / v).

[0021] In some embodiments, the stable formulation comprises a salt.

[0022] In some embodiments, the salt is sodium chloride. In some embodiments, the salt is potassium chloride. In some embodiments, the salt is magnesium chloride. In some embodiments, the salt is calcium chloride.

[0023] In some embodiments, the stable formulation comprises a salt, wherein the salt is present at concentrations of 5 mM to 300 mM. In some embodiments, the stable formulation comprises a salt, wherein the salt is present at concentrations of 10 mM to 250 mM. In some embodiments, the stable formulation comprises a salt, wherein the salt is present at concentrations of 25 mM to 200 mM. In some embodiments, the stable formulation comprises a salt, wherein the salt is present at concentrations of 50 mM to 150 mM. In some embodiments, the stable formulation comprises a salt, wherein the salt ispresent at concentrations of 40 mM to 80 mM. In some embodiments, the salt is present at concentrations of 50 mM to 75 mM. In some embodiments, the salt is present at a concentration of 200 mM. In some embodiments, the salt is present at a concentration of 175 mM. In some embodiments, the salt is present at a concentration of 150 mM. In some embodiments, the salt is present at a concentration of 125 mM. In some embodiments, the salt is present at a concentration of 100 mM. In some embodiments, the salt is present at a concentration of 80 mM. In some embodiments, the salt is present at a concentration of 75 mM. In some embodiments, the salt is present at a concentration of 70 mM. In some embodiments, the salt is present at a concentration of 65 mM. In some embodiments, the salt is present at a concentration of 60 mM. In some embodiments, the salt is present at a concentration of 55 mM. In some embodiments, the salt is present at a concentration of 50 mM. In some embodiments, the salt is present at a concentration of 45 mM. In some embodiments, the salt is present at a concentration of 40 mM. In some embodiments, the salt is present at a concentration of 35 mM. In some embodiments, the salt is present at a concentration of 30 mM. In some embodiments, the salt is present at a concentration of 25 mM. In some embodiments, the salt is present at a concentration of 20 mM. In some embodiments, the salt is present at a concentration of 15 mM. In some embodiments, the salt is present at a concentration of 10 mM.

[0024] In some embodiments, the stable formulation comprises an amino acid.

[0025] In some embodiments, the amino acid is a basic amino acid. In some embodiments, the amino acid is an acidic amino acid. In some embodiments, the amino acid is lysine. In some embodiments, the amino acid is arginine. In some embodiments, the amino acid is glutamate. In some embodiments, the amino acid is aspartate. In some embodiments, the amino acid is alanine. In some embodiments, the amino acid is proline. In some embodiments, the amino acid is methionine. In some embodiments, the amino acid is glycine.

[0026] In some embodiments, the amino acid is present at a concentration of 15 mM to 150 mM. In some embodiments, the amino acid is present at a concentration of 25 mM to 100 mM. In some embodiments, the amino acid is present at a concentration of 75 mM.

[0027] In one aspect, the present invention provides, among other things, a stable formulation comprising an ant-interleukin- 1 receptor 1 (IL1R1) antibody, a stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein theformulation comprises 20mM to 60 mM acetate, a basic amino acid, and pH of 4.2 to 5.5, wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT), and wherein the anti-ILlRl antibody is present at a concentration of greater than 80 mg / ml.

[0028] In some embodiments, the stable formulation has a pH of 5.0 to 5.5. In some embodiments, the stable formulation has a pH of 5.1 to 5.3. In some embodiments, the stable formulation has a pH of 5.2.

[0029] In one aspect, the present invention provides, among other things, a stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises 20 mM to 60 mM acetate, a sugar, and a pH of 4.2 to 5.7, and wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT), and wherein the anti-ILlRl antibody is present at a concentration of greater than 80 mg / ml.

[0030]

[0031] In one aspect, the present invention provides, among other things, a stable formulation comprising an ant-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises 10 mM to 50 mM histidine, an amino acid, and a pH of 5.5 to 6.5, and wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT), and wherein the anti-ILlRl antibody is present at a concentration of greater than 80 mg / ml.

[0032] In some embodiments, the amino acid is a basic amino acid, an acidic amino acid, proline or a combination thereof.

[0033] In one aspect, the present invention provides, among other things, a stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises 10 mM to 50 mM histidine, a sugar, and a pH of 5.5 to 6.5, and wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT), and wherein the anti-ILlRl antibody is present at a concentration of greater than 80 mg / ml.

[0034] In some embodiments, the stable formulation has a pH of 4.7 to 5.7. In some embodiments, the stable formulation has a pH of 5.0 to 5.4. In some embodiments, the stable formulation has a pH of 5.5to 6.5. In some embodiments, the stable formulation has a pH of 6. Oto 6.3. In some embodiments, the stable formulation has a pH of 6.1.

[0035] In one aspect, the present invention provides, among other things, a stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises 25 mM to 75 mM succinate, a basic amino acid, and a pH of 5.0 to 6.0, and wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT), and wherein the anti-ILlRl antibody is present at a concentration of greater than 80 mg / ml.

[0036] In one aspect, the present invention provides, among other things, a stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises 25 mM to 75 mM succinate, a salt, and a pH of 5.0 to 6.0, and wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT), and wherein the anti-ILlRl antibody is present at a concentration of greater than 80 mg / ml.

[0037] In one aspect, the present invention provides, among other things, a stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises 20 mM to 60 mM succinate, a sugar, and a pH of 5.0 to 6.0, and wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT), and wherein the anti-ILlRl antibody is present at a concentration of greater than 80 mg / ml.

[0038] In some embodiments, the stable formulation has a pH of 5.0 to 6.0. In some embodiments, the pH is 5.2 to 5.8. In some embodiments, the pH is 5.4 to 5.7. In some embodiments, the pH is 5.6.

[0039] In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 50 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 60 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 70 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 80 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 90 mg / ml. In some embodiments, the stable formulation comprises the anti- IL1R1 antibody at a concentration of greater than 100 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 110 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 120 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 125 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 130 mg / ml. In some embodiments, the stable formulation comprises the anti- IL1R1 antibody at a concentration of greater than 140 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 150 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 160 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 170 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 180 mg / ml.

[0040] In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 50 mg / mL to 250 mg / mL. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 80 mg / mL to 200 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 100 mg / mL to 150 mg / mL. In some embodiments, the stable formulation comprises the anti- IL1R1 antibody at a concentration of 50 mg / mL to 150 mg / mL. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 135 mg / mL to 165 mg / mL. In some embodiments, the stable formulation comprises the anti-ILlRl antibodyat a concentration of 145 mg / mL to 160 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 50 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 80 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 100 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 110 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 120 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 125 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 130 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 135 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 140 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 145 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 150 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 155 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 160 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 165 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 170 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 175 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 180 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 185 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 190 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 200 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 225 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 250 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 275 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 300 mg / mL.

[0041] In one aspect, the present invention provides, among other things, a stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises: 150 mg / mL anti-ILlRl antibody, 25 mM sodium acetate, a pH 5.2, 7% w / v sucrose, and 0.02% w / v polysorbate 20, wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT).

[0042] In one aspect, the present invention provides, among other things, a stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises: 150 mg / mL anti-ILlRl antibody, 25 mM sodium acetate, a pH of 4.5 - 5.7, 7% w / v sucrose, and 0.02% w / v polysorbate 20, wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT). In some embodiments, the stable formulation has a pH of 4.5 to 5.0. In some embodiments, the stable formulation has a pH of 4.7 to 5.7. In some embodiments, the stable formulation has a pH of 5.0 to 5.4.

[0043] In one aspect, the present invention provides, among other things, a stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises: the anti-ILlRl antibody at a concentration of 135 mg / mL to 165 mg / mL, 25 mM sodium acetate, a pH of 4.7 to 5.7, 7% w / v sucrose, and 0.02% w / v polysorbate 20, wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT). In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 145-160 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 150 mg / ml. In some embodiments, the stable formulation has a pH of 5.0 to 5.4. In some embodiments, the stable formulation has a pH of 5.2.

[0044] In one aspect, the present invention provides, among other things, a stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises: the anti-ILlRl antibody at a concentration of 145 mg / mL to 160 mg / mL, 25 mM sodium acetate, a pH of 5.0 to 5.4, 7% w / v sucrose, and 0.02% w / v polysorbate 20, wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT). In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 150 mg / ml. In some embodiments, the stable formulation has a pH of 5.2.

[0045] In one aspect, the present invention provides, among other things, a stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises: 150 mg / mL anti-ILlRl antibody, 25 mM sodium acetate, a pH of 5.2, 7% w / v sucrose, and 0.02% w / v polysorbate 20, wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT).

[0046] In some embodiments, the pH is 4.5. In some embodiments, the pH is 4.6. In some embodiments, the pH is 4.7. In some embodiments, the pH is 4.8. In some embodiments, the pH is 4.9. In some embodiments, the pH is 5.0. In some embodiments, the pH is 5.1. In some embodiments, the pH is 5.2. In some embodiments, the pH is 5.3. In some embodiments, the pH is 5.4. In some embodiments, the pH is 5.5. In some embodiments, the pH is 5.6. In some embodiments, the pH is 5.7.

[0047] In one aspect, the present invention provides, among other things, a stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises: the anti-ILlRl antibody at a concentration of 135 mg / mL to 165 mg / mL, 25 mM sodium acetate, a pH of 4.4 to 5.4, 25.9 mg / ml proline, and 0.02% w / v polysorbate 20, wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 of SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT). In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 145-160 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 150 mg / ml. In some embodiments, the stable formulation has a pH of 4.6 to 5.2. In some embodiments, the stable formulation has a pH of 4.7 to 5.1. In some embodiments, the stable formulation has a pH of 4.9 to 5.2. In some embodiments, the stable formulation has a pH of 4.7 to 5.1. In some embodiments, the stable formulation has a pH of 4.9.

[0048] In one aspect, the present invention provides, among other things, a stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises: the anti-ILlRl antibody at a concentration of 135 mg / mL to 165mg / mL, 25 mM sodium acetate, a pH of 4.6 to 5.2, 25.9 mg / ml proline, and 0.02% w / v polysorbate 20, wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 of SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT). In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 145-160 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 150 mg / ml. In some embodiments, the stable formulation has a pH of 4.7 to 5.1. In some embodiments, the stable formulation has a pH of 4.9.

[0049] In one aspect, the present invention provides, among other things, a stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises: the anti-ILlRl antibody at a concentration of 145 mg / mL to 160 mg / mL, 25 mM sodium acetate, a pH of 4.7 to 5.1, 25.9 mg / ml proline, and 0.02% w / v polysorbate 20, wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 of SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT). In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 150 mg / ml. In some embodiments, the stable formulation has a pH of 4.9.

[0050] In one aspect, the present invention provides, among other things, a stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises: 150 mg / mL anti-ILlRl antibody, 25 mM sodium acetate, a pH of 4.4 to 5.4, 25.9 mg / ml proline, and 0.02% w / v polysorbate 20, wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 of SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT). In some embodiments, the stable formulation has a pH of 4.6 to 5.2. In some embodiments, the stable formulation has a pH of 4.7 to 5.1.

[0051] In some embodiments, the pH is 4.4. In some embodiments, the pH is 4.5. In some embodiments, the pH is 4.6. In some embodiments, the pH is 4.7. In some embodiments, the pH is 4.8. In some embodiments, the pH is 4.9. In some embodiments, thepH is 5.0. In some embodiments, the pH is 5.1. In some embodiments, the pH is 5.2. In some embodiments, the pH is 5.3. In some embodiments, the pH is 5.4.

[0052] In one aspect, the present invention provides, among other things, a stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises: 150 mg / mL anti-ILlRl antibody, 25 mM sodium acetate, a pH 5.0, 25.9 mg / ml proline, and 0.02% w / v polysorbate 20, wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 of SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT).

[0053] In one aspect, the present invention provides, among other things, a stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises: 150 mg / mL anti-ILlRl antibody, 25 mM sodium acetate, a pH 4.9, 25.9 mg / ml proline, and 0.02% w / v polysorbate 20, wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 of SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT).

[0054] In one aspect, the present invention provides, among other things, a stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises: 150 mg / mL anti-ILlRl antibody, 25 mM sodium acetate, a pH 5.0, 66.5 mM arginine, 3.5 % w / v sucrose, and 0.02 % w / v polysorbate 20, wherein the anti- IL1R1 antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT).

[0055] In some embodiments, the stable formulation comprises the anti-ILlRl antibody comprises a variable heavy chain (VH) of SEQ ID NO: 3 and a variable light chain (VL) of SEQ ID NO: 4.

[0056] In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the anti-ILlRl antibody comprises a IgG2 Fc region.

[0057] In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the anti-ILlRl antibody comprises a heavy chain of SEQ ID NO: 1 and a light chain of SEQ ID NO: 2.

[0058] In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein at least the 95% of the anti-ILlRl antibody exists as a monomer after 3 rounds of freeze and thaw cycles.

[0059] In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein at least 98% of the anti-ILlRl antibody exists as a monomer after 3 rounds of freeze and thaw cycles.

[0060] In some embodiments, the amount of HMW species in the formulation increases less than 0.2 % after 3 rounds of freeze and thaw cycles.

[0061] In some embodiments, the amount of HMW species in the formulation increases less than 0.3% after 6 rounds of freeze and thaw cycles.

[0062] In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 10% upon storage at 5° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 9% upon storage at 5° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 8% upon storage at 5° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 7% upon storage at 5° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 6% upon storage at 5° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 5% upon storage at 5° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 4% upon storage at 5° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 3% upon storage at 5° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 2%upon storage at 5° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 1% upon storage at 5° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 0.8% upon storage at 5° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 0.6% upon storage at 5° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 0.5% upon storage at 5° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 0.4% upon storage at 5° C for 4 weeks. In some embodiments, upon storage at 5°C for 4 weeks, the amount of HMW species in the formulation does not substantially increase.

[0063] In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 35%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases 30% or less. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases 25% or less. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 20%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 15%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 10%. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 5% upon storage at 25° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 4% upon storage at 25° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 3% upon storage at 25° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 2% upon storage at 25° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 1.5% upon storage at 25° C for 4 weeks. In some embodiments, the stableformulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 1.4% upon storage at 25° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 1.2% upon storage at 25° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 1% upon storage at 25° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 0.8% upon storage at 25° C for 4 weeks. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation does not substantially increase.

[0064] In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 255%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 200%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 100%. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 50% upon storage at 40° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 38% upon storage at 40° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 50% upon storage at 35° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 40% upon storage at 40° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 30% upon storage at 40° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 25% upon storage at 40° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 20% upon storage at 40° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 25% upon storage at 40° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody,wherein the amount of HMW species in the formulation increases less than 20% upon storage at 40° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 15% upon storage at 40° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 10% upon storage at 40° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 5% upon storage at 40° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of HMW species in the formulation increases less than 4% upon storage at 40° C for 4 weeks.

[0065] In some embodiments, upon storage at 5°C for 4 weeks, the amount of fragments in the formulation increases less than 15%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of fragments in the formulation increases less than 14%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of fragments in the formulation increases less than 13%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of fragments in the formulation increases less than 12%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of fragments in the formulation increases less than 11%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of fragments in the formulation increases less than 10%. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein fragments in the formulation increases less than 1% upon storage at 5° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein fragments in the formulation increases less than 0.5% upon storage at 5° C for 4 weeks. In some embodiments, the stable formulation comprises the anti- IL1R1 antibody, wherein fragments in the formulation increases less than 0.4% upon storage at 5° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein fragments in the formulation increases less than 0.3% upon storage at 5° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein fragments in the formulation increases less than 0.2% upon storage at 5° C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein fragments in the formulation increases less than 0.1% upon storage at 5° C for 4 weeks. In some embodiments, upon storage at 5°C for 4 weeks, the amount of fragments in the formulation does not substantially increase.

[0066] In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein fragments in the formulation increases less than 25% upon storage at 25°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein fragments in the formulation increases less than 22% upon storage at 25°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein fragments in the formulation increases less than 20% upon storage at 25°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein fragments in the formulation increases less than 1% upon storage at 25°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein fragments in the formulation increases less than 0.5% upon storage at 25 °C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein fragments in the formulation increases less than 0.4% upon storage at 25 °C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein fragments in the formulation increases less than 0.3% upon storage at 25 °C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein fragments in the formulation increases less than 0.2% upon storage at 25 °C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein fragments in the formulation increases less than 0.1% upon storage at 25 °C for 4 weeks. In some embodiments, upon storage at 25°C for 4 weeks, the amount of fragments in the formulation does not substantially increase.

[0067] In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of fragments in the formulation increases less than 90% upon storage at 40°C for 4 weeks. In some embodiments, the stable formulation comprises the anti- IL1R1 antibody, wherein the amount of fragments in the formulation increases less than 86% upon storage at 40°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of fragments in the formulation increases less than 5% upon storage at 40°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of fragments in the formulation increases less than 4% upon storage at 40°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of fragments in the formulation increases less than 3 % upon storage at 40°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of fragments in the formulation increases less than 2 % upon storage at 40°C for 4 weeks. Insome embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of fragments in the formulation increases less than 1 % upon storage at 40°C for 4 weeks. In some embodiments, upon storage at 40°C, for 4 weeks the amount of fragments in the formulation does not substantially increase.

[0068] In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation increases less than 2% upon storage at 5°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation increases less than 1.5% upon storage at 5 °C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation increases less than 1.2% upon storage at 5°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation increases less than 1% upon storage at 5°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation increases less than 0.5% upon storage at 5°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation increases less than 0.4% upon storage at 5°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation increases less than 0.3% upon storage at 5 °C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation increases less than 0.2% upon storage at 5°C for 4 weeks. In some embodiments, the stable formulation comprises the anti- IL1R1 antibody, wherein the amount of acidic species in the formulation increases less than 0.1% upon storage at 5°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation does not substantially increase upon storage 5°C for 4 weeks.

[0069] In some embodiments, upon storage at 25°C for 4 weeks, the amount of acidic species in the formulation increases less than 2%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of acidic species in the formulation increases less than 1.5%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of acidic species in the formulation increases less than 1.2%. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation increases less than 1 % upon storage at 25 °C for 4 weeks. In some embodiments, the stableformulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation increases less than 0.5 % upon storage at 25°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation increases less than 0.4 % upon storage at 25°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation increases less than 0.3 % upon storage at 25°C for 4 weeks. In some embodiments, the stable formulation comprises the anti- IL1R1 antibody, wherein the amount of acidic species in the formulation increases less than 0.2 % upon storage at 25°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation increases less than 0.1 % upon storage at 25°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation does not substantially increase upon storage at 25°C for 4 weeks.

[0070] In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation increases less than 30% upon storage at 40°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation increases less than 26% upon storage at 40°C for 4 weeks. In some embodiments, upon storage at 40°C for 4 weeks, the amount of acidic species in the formulation increases less than 25%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of acidic species in the formulation increases less than 20%. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation increases less than 10% upon storage at 40°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation increases less than 8% upon storage at 40°C for 4 weeks. In some embodiments, the stable formulation comprises the anti-ILlRl antibody, wherein the amount of acidic species in the formulation increases less than 7% upon storage at 40°C for 4 weeks.

[0071] In some embodiments, the stable formulation has a viscosity of less than 25 cp at 20 °C. In some embodiments, the stable formulation has a viscosity of 15 cp or less at 20BRIEF DESCRIPTION OF THE DRAWINGS

[0072] The drawings herein are for illustrative purposes only and should not be limiting.

[0073] FIG. 1 is an exemplary photograph of anti-ILl-Rl antibody formulations, showing their visual appearance after short-term storage at 25 °C and 40 °C.

[0074] FIG. 2 depicts an exemplary bar graph of the experimentally determined diffusion interaction coefficients (KD) for each formulation at an antibody concentration ranging from 1 mg / mL to 20 mg / mL.

[0075] FIG. 3 depicts an exemplary bar graph of the experimentally determined second virial coefficients (B22) for each formulation at an antibody concentration ranging from 1 mg / mL to 20 mg / mL.

[0076] FIG. 4 depicts exemplary plots showing viscosity of the formulations versus antibody concentration, which ranges from 100 mg / mL to 180 mg / mL.

[0077] FIG. 5 depicts an exemplary bar chart showing the percent change in levels of high molecular weight species of antibody in formulations after three (FT3) or six (FT6) cycles of freeze / thaw agitation, wherein the antibody concentration is 150 mg / mL.

[0078] FIG. 6 depicts an exemplary bar chart showing the percent change in levels of high molecular weight species of antibody in formulations by SEC after a storage period of 1 month at 5 °C and 25 °C, wherein the antibody concentration is 150 mg / mL.

[0079] FIG. 7 depicts an exemplary bar chart showing the percent change in levels of high molecular weight species of antibody in in formulations by SEC after a storage period of 1 month at 40 °C, wherein the antibody concentration is 150 mg / mL.

[0080] FIG. 8 depicts exemplary bar charts showing the percent change in levels of acidic and basic charge variants in formulations by icIEF after a storage period of 1 month at 5 °C, 25 °C, and 40 °C, wherein the antibody concentration is 150 mg / mL.

[0081] FIG. 9 depicts an exemplary bar chart showing the percent change in levels of antibody fragment as characterized by NR-CE-SDS after a storage period of 1 month at 5 °C, 25 °C, and 40 °C, wherein the antibody concentration is 150 mg / mL.

[0082] FIG. 10 depicts an exemplary graph showing the change in the %HMW species of Abl over time in samples with varying levels of acidic species at baseline.DEFINITIONS

[0083] In order for the present invention to be more readily understood, certain terms are first defined below. Additional definitions for the following terms and other terms are set forth throughout the specification. The publications and other reference materials referenced herein to describe the background of the invention and to provide additional detail regarding its practice are hereby incorporated by reference.

[0084] Any numerical values used in this application are meant to cover any variations within the standard deviation or normal fluctuations appreciated by one of ordinary skill in the relevant art.

[0085] Acidic Species: As used herein, the term “acidic species” refers to the variants of a protein, e.g., an antibody or antigen binding fragment thereof, which are characterized by an overall acidic charge relative to the main species. Acidic species can be detected by charge based separation techniques such as, for example and without limitation, isoelectric focusing (IEF) gel electrophoresis, capillary isoelectric focusing (cIEF) gel electrophoresis, cation exchange chromatography (CEX), and anion exchange chromatography (AEX). In some embodiments, the level of acidic species is determined by imaging capillary isoelectric focusing (iCIEF).

[0086] Acidic species are variants with lower apparent pl relative to the main species when antibodies are analyzed using IEF based methods. When analyzed by chromatographybased methods, acidic species are defined based on their retention times relative to the main peak. Acidic species are the variants that elute earlier than the main peak from AEX.

[0087] Acidic species of an antibody may include charge variants, structure variants, and / or fragmentation variants. Exemplary charge variants include, but are not limited to, deamidation variants, afucosylation variants, methylglyoxal variants, glycation variants, and citric acid variants. Exemplary structure variants include, but are not limited to, glycosylation variants and acetonation variants. Exemplary fragmentation variants include, but are not limited to, any truncated protein species from the protein of interest due to dissociation of peptide chain, enzymatic and / or chemical modifications, including, but not limited to, Fc and Fab fragments, fragments missing a Fab, fragments missing a heavy chain variable domain, C-terminal truncation variants, variants with the excision of N-terminal Asp in the light chain, and variants having N-terminal truncation of the light chain. Other acidic species variants also include, but are not limited to, unpaired disulfides, host cell proteins, and hostnucleic acids, chromatographic materials, and media components. The acidic species may be the result of product preparation, storage, and / or purification.

[0088] Amino acid: As used herein, the term “amino acid,” in its broadest sense, refers to any compound and / or substance that can be incorporated into a polypeptide chain. In some embodiments, an amino acid has the general structure H2N-C(H)(R)-COHO. In some embodiments, an amino acid is a naturally occurring amino acid. In some embodiments, an amino acid is a synthetic amino acid; in some embodiments, an amino acid is a d-amino acid; in some embodiments, an amino acid is an 1-amino acid. In some embodiments, an amino acid is a standard amino acid, which refers to any of the twenty standard 1-amino acids commonly found in naturally occurring peptides. In some embodiments, an amino acid is a nonstandard amino acid, which refers to any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or obtained from a natural source. In some embodiments, an amino acid is a synthetic amino acid, which encompasses chemically modified amino acids, including but not limited to salts, amino acid derivatives (such as amides), and / or substitutions. Amino acids, including carboxyl- and / or amino-terminal amino acids in peptides, can be modified by methylation, amidation, acetylation, protecting groups, and / or substitution with other chemical groups that can change the peptide’s circulating half-life without adversely affecting their activity. Amino acids may participate in a disulfide bond. Amino acids may comprise one or posttranslational modifications, such as association with one or more chemical entities (e.g., methyl groups, acetate groups, acetyl groups, phosphate groups, formyl moieties, isoprenoid groups, sulfate groups, polyethylene glycol moieties, lipid moieties, carbohydrate moieties, biotin moieties, etc.). The term “amino acid” is used interchangeably with “amino acid residue,” and may refer to a free amino acid and / or to an amino acid residue of a peptide. It will be apparent from the context in which the term is used whether it refers to a free amino acid or a residue of a peptide.

[0089] Diluent: As used herein, the term "diluent" refers to a pharmaceutically acceptable ( e.g., safe and non-toxic for administration to a human) diluting substance useful for the preparation of a reconstituted formulation. Exemplary diluents include sterile water, bacteriostatic water for injection (BWFI), a pH buffered solution (e.g. phosphate-buffered saline), sterile saline solution, Ringer's solution or dextrose solution.

[0090] Delivery. As used herein, the term “delivery” encompasses both local, subcutaneous and systemic delivery.

[0091] Half-life-. As used herein, the term “half-life” is the time required for a quantity such as nucleic acid or protein concentration or activity to fall to half of its value as measured at the beginning of a time period.

[0092] IL1R1-. As used herein, the terms “Interleukin 1, Receptor Type 1”, IL-1R1” or“IL1R1” refer to a cytokine receptor that belongs to the interleukin- 1 receptor family. IL-1R1 is also known as CD121 Antigen-Like Family Member A, CD121A, CD121a Antigen, IL- 1RA, D2S1473, P80, EC 3.2.2.6, or CRM03. IL-1R1 is a receptor for interleukin- 1 alpha (ILla), interleukin-1 beta (ILip), and interleukin- 1 receptor antagonist (ILIRa). It is an important mediator involved in many cytokine-induced immune and inflammatory responses (see PCT Publication No. W02004022718, the entire contents of which, including the sequences described therein, are incorporated herein by reference). Upon binding of a cytokine, e.g., ILla and IL-ip, to IL-1R1, a shared co-receptor, IL-lRAcP, is recruited by binding to the composite surface of the cytokine and primary receptor complex, resulting in the creation of a trimeric signaling complex. In the resting state, IL-1R1 and the co-acceptor, IL-lRAcP, are present on the cell membrane. Once IL-1 (either IL- la or IL-ip) binds to IL- 1R1, a structural change occurs that allows IL-lRAcP to bind to IL-1R1. The trimeric complex allows for the approximation of the TIR domains of each receptor chain. MyD88 then binds to the TIR domains. The binding of MyD88 triggers a cascade of kinases that produce a strong pro-inflammatory signal leading to activation of NFKB.

[0093] Stability: As used herein, the term "stable" refers to the ability of the therapeutic agent (e.g., an antibody) to maintain its therapeutic efficacy (e.g., all or the majority of its intended biological activity and / or physiochemical integrity) over extended periods of time. The stability of a therapeutic agent, and the capability of the pharmaceutical composition to maintain stability of such therapeutic agent, may be assessed over extended periods of time (e.g., for at least 1, 3, 6, 12, 18, 24, 30, 36 months or more). In general, pharmaceutical compositions described herein have been formulated such that they are capable of stabilizing, or alternatively slowing or preventing the degradation, of one or more therapeutic agents formulated therewith (e.g., antibodies). In the context of a formulation a stable formulation is one in which the therapeutic agent therein essentially retains its physical and / or chemical integrity and biological activity upon storage and during processes (such asfreeze / thaw, mechanical mixing and lyophilization). For protein stability, it can be measure by formation of high molecular weight (HMW) aggregates, loss of enzyme activity, generation of peptide fragments and shift of charge profiles. For the purpose of the present application, the term high molecular weight species (HMW) of the product and “aggregates” are used interchangeably.

[0094] Suitable for subcutaneous delivery: As used herein, the phrase "suitable for subcutaneous delivery" or "formulation for subcutaneous delivery" as it relates to the pharmaceutical compositions of the present invention generally refers to the stability, viscosity, and solubility properties of such compositions, as well as the ability of such compositions to deliver an effective amount of antibody contained therein to the targeted site of delivery.

[0095] Patient: As used herein, the term “patient” or “subject” refers to any organism to which a provided composition may be administered, e.g., for experimental, diagnostic, prophylactic, cosmetic, and / or therapeutic purposes. Typical patients include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and / or humans). In some embodiments, a patient is a human. A human includes pre- and post-natal forms.

[0096] Pharmaceutically acceptable-. The term “pharmaceutically acceptable” as used herein, refers to substances that, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0097] Subject-. As used herein, the term “subject” refers to a human or any non- human animal (e.g., mouse, rat, rabbit, dog, cat, cattle, swine, sheep, horse or primate). A human includes pre- and post-natal forms. In many embodiments, a subject is a human being. A subject can be a patient, which refers to a human presenting to a medical provider for diagnosis or treatment of a disease. The term “subject” is used herein interchangeably with “individual” or “patient.” A subject can be afflicted with or is susceptible to a disease or disorder but may or may not display symptoms of the disease or disorder.

[0098] Substantially. As used herein, the term “substantially” refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and / or proceed to completeness orachieve or avoid an absolute result. The term “substantially” is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.

[0099] Treating-. As used herein, the term “treat,” “treatment,” or “treating” refers to any method used to partially or completely alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of and / or reduce incidence of one or more symptoms or features of a particular disease, disorder, and / or condition. Treatment may be administered to a subject who does not exhibit signs of a disease and / or exhibits only early signs of the disease for the purpose of decreasing the risk of developing pathology associated with the disease.DETAILED DESCRIPTION

[0100] The present invention provides, among other things, stable formulations comprising an anti-Interleukin 1 Receptor 1 (IL1R1) antibody at a concentration of greater than 80 mg / ml with a pH ranging from 4.4 to 6.5, wherein the amount of HMW species in the formulation increases less than 2% upon storage at 25° C for at least 4 weeks. In some embodiments, the amount of HMW species in the formulation increases less than 40% upon storage at 40° C. for 4 weeks. In some embodiments, the stable formulations comprise an anti-interleukin 1 receptor 1 (IL1R1) antibody at a concentration of greater than 80 mg / ml with a pH ranging from 4.0 to 7.4 and less than 130 mM of arginine. In some embodiments, the formulation is suitable for subcutaneous delivery. In some embodiments, stable formulations of the present invention are suitable for treating diseases and disorders associated with IL1R1.

[0101] Various aspects of the invention are described in detail in the following sections. The use of sections is not meant to limit the invention. Each section can apply to any aspect of the invention. In this application, the use of “or” means “and / or” unless stated otherwise, and in the context of a range of values, the use of the term “between” means a range between X and Y that includes the endpoints X and Y.Anti-Interleukin 1 Receptor 1 (IL1R1 ) Antibodies

[0102] In some embodiments, inventive compositions and methods provided by the present invention are used to deliver an anti-ILlRl antibody to a subject in need.Anti-ILIRI Heavy Chain Amino Acid Sequence

[0103] EVQLMQSGAEVKKPGESLKISCKGSGYSFSFHWIAWVRQMPGKGLE WMGIIHPGASDTRYSPSFQGQVTISADNSNSATYLQWSSLKASDTAMYFCARQRELD YFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVE RKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNW YVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIE KTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG K (SEQ ID NO: 1)

[0104] In some embodiments, an anti-ILlRl antibody comprises a heavy chain that is at least 85% identical to SEQ ID NO: 1. In some embodiments, an anti-ILlRl antibody comprises a heavy chain that is at least 90% identical to SEQ ID NO: 1. In some embodiments, an anti-ILlRl antibody comprises a heavy chain that is at least 92% identical to SEQ ID NO: 1. In some embodiments, an anti-ILlRl antibody comprises a heavy chain that is at least 93% identical to SEQ ID NO: 1. In some embodiments, an anti-ILlRl antibody comprises a heavy chain that is at least 94% identical to SEQ ID NO: 1. In some embodiments, an anti-ILlRl antibody comprises a heavy chain that is at least 95% identical to SEQ ID NO: 1. In some embodiments, an anti-ILlRl antibody comprises a heavy chain that is at least 96% identical to SEQ ID NO: 1. In some embodiments, an anti-ILlRl antibody comprises a heavy chain that is at least 97% identical to SEQ ID NO: 1. In some embodiments, an anti-ILlRl antibody comprises a heavy chain that is at least 98% identical to SEQ ID NO: 1. In some embodiments, an anti-ILlRl antibody comprises a heavy chain that is at least 99% identical to SEQ ID NO: 1. In some embodiments, an anti-ILlRl antibody comprises a heavy chain of SEQ ID NO: 1.Anti-ILlRl Light Chain Amino Acid Sequence

[0105] EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKY ASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPLTFGGGTKVEIKRT VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 2)

[0106] In some embodiments, an anti-ILlRl antibody comprises a light chain that is at least 85% identical to SEQ ID NO: 2. In some embodiments, an anti-ILlRl antibody comprises a light chain that is at least 90% identical to SEQ ID NO:2. In some embodiments, an anti-ILlRl antibody comprises a light chain that is at least 92% identical to SEQ ID NO:2. In some embodiments, an anti-ILlRl antibody comprises a light chain that is at least 93% identical to SEQ ID NO:2. In some embodiments, an anti-ILlRl antibody comprises a light chain that is at least 94% identical to SEQ ID NO:2. In some embodiments, an anti-ILlRl antibody comprises a light chain that is at least 95% identical to SEQ ID NO:2. In some embodiments, an anti-ILlRl antibody comprises a light chain that is at least 96% identical to SEQ ID NO:2. In some embodiments, an anti-ILlRl antibody comprises a light chain that is at least 97% identical to SEQ ID NO:2. In some embodiments, an anti-ILlRl antibody comprises a light chain that is at least 98% identical to SEQ ID NO:2. In some embodiments, an anti-ILlRl antibody comprises a light chain that is at least 99% identical to SEQ ID NO:2. In some embodiments, an anti-ILlRl antibody comprises a light chain of SEQ ID NO:2.Anti-ILlRl Heavy Chain Variable Domain (VH) Amino Acid Sequence

[0107] EVQLMQSGAEVKKPGESLKISCKGSGYSFSFHWIAWVRQMPGKGLE WMGIIHPGASDTRYSPSFQGQVTISADNSNSATYLQWSSLKASDTAMYFCARQRELD YFDYWGQGTLVTVSS (SEQ ID NO: 3)

[0108] In some embodiments, an anti-ILlRl antibody comprises a VH that is at least 85% identical to SEQ ID NOG. In some embodiments, an anti-ILlRl antibody comprises a VH that is at least 90% identical to SEQ ID NOG. In some embodiments, an anti-ILlRl antibody comprises a VH that is at least 92% identical to SEQ ID NOG. In some embodiments, an anti-ILlRl antibody comprises a VH that is at least 93% identical to SEQ ID NOG. In some embodiments, an anti-ILlRl antibody comprises a VH that is at least 94% identical to SEQ ID NOG. In some embodiments, an anti-ILlRl antibody comprises a VH that is at least 95% identical to SEQ ID NOG. In some embodiments, an anti-ILlRl antibody comprises a VH that is at least 96% identical to SEQ ID NOG. In some embodiments, an anti-ILlRl antibody comprises a VH that is at least 97% identical to SEQ ID NOG. In some embodiments, an anti-ILlRl antibody comprises a VH that is at least 98% identical to SEQ ID NOG. In some embodiments, an anti-ILlRl antibody comprises a VH that is at least 99% identical to SEQ ID NOG. In some embodiments, an anti-ILlRl antibody comprises a VH of SEQ ID NOG.Anti-ILIRI Light Chain Variable Domain (VL) Amino Acid Sequence

[0109] EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKY ASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPLTFGGGTKVEIK (SEQ ID NO: 4)

[0110] In some embodiments, an anti-ILlRl antibody comprises a VL that is at least 85% identical to SEQ ID NO: 4. In some embodiments, an anti-ILlRl antibody comprises a VL that is at least 90% identical to SEQ ID NO:4. In some embodiments, an anti-ILlRl antibody comprises a VL that is at least 92% identical to SEQ ID NO:4. In some embodiments, an anti-ILlRl antibody comprises a VL that is at least 93% identical to SEQ ID NO:4. In some embodiments, an anti-ILlRl antibody comprises a VL that is at least 94% identical to SEQ ID NO:4. In some embodiments, an anti-ILlRl antibody comprises a VL that is at least 95% identical to SEQ ID NO:4. In some embodiments, an anti-ILlRl antibody comprises a VL that is at least 96% identical to SEQ ID NO:4. In some embodiments, an anti-ILlRl antibody comprises a VL that is at least 97% identical to SEQ ID NO:4. In some embodiments, an anti-ILlRl antibody comprises a VL that is at least 98% identical to SEQ ID NO:4. In some embodiments, an anti-ILlRl antibody comprises a VL that is at least 99% identical to SEQ ID NO:4. In some embodiments, an anti-ILlRl antibody comprises a VL of SEQ ID NO:4.Table A. CDR amino acids sequencesAnti-ILlRl Heavy Chain Amino Acid Sequence - Constant DomainASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 11)Anti-ILlRl Light Chain Amino Acid Sequence - Constant DomainRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ IDNO: 12)

[0111] In some embodiments of the invention, an anti-ILl-Rl antibody comprises a heavy chain complementarity-determining region 1 (HCDR1) defined by SEQ ID NO: 5, a heavy chain complementarity-determining region 2 (HCDR2) defined by SEQ ID NO: 6, and a heavy chain complementarity-determining region 3 (HCDR3) defined by SEQ ID NO: 7; and a light chain complementarity-determining region 1 (LCDR1) defined by SEQ ID NO: 8, a light chain complementarity-determining region 2 (LCDR2) defined by SEQ ID NO: 9, and a light chain complementarity-determining region 3 (LCDR3) defined by SEQ ID NO: 10.Formulation

[0112] Antibody aggregation (i.e., HMW species of antibody) is a common problem in antibody formulation, and often results from increased concentration of the antibody. The presence of aggregates in antibody drug products can induce adverse immune responses in patients that may affect safety and efficacy, and so it is of concern to both manufacturers and regulatory agencies. The instant present disclosure provides a means for achieving a high concentration and low antibody aggregation formulation. Formulations of the present disclosure can be advantageous for therapeutic purposes, as they are high in protein concentration suitable for delivery in small volume injections.

[0113] The majority of biologic products (including antibodies) are subject to numerous degradative processes which frequently arise from non-enzymatic reactions in solution (e.g., oxidation and deamidation). These reactions may have a long-term impact on product stability, safety and efficacy. These degradation reactions can be slowed, if not eliminated, by storage of product at subzero temperatures, thus gaining a tremendous advantage for the manufacturer in terms of flexibility and availability of supplies over the product life-cycle. Although freezing is often the safest and most reliable method of biologies product storage, it has inherent risks. Freezing and thawing can induce stress in proteins through cold denaturation, by introducing ice-liquid interfaces, and by freeze- concentration (cryoconcentration) of solutes when the water crystallizes.

[0114] Stability of a protein in a formulation may also be defined in terms of the percentage of monomer, aggregate (HMW), or fragment, charged species, or combinations thereof, of the protein in the formulation observed over time. In one aspect of the presentdisclosure, a stable formulation is a formulation having less than 10% to less than 5% of the protein being present as aggregate in the formulation upon storage at 5° C or 25 ° C.

[0115] In some embodiments, the present disclosure also provides a method for adjusting a certain characteristic, such as the osmolality and / or viscosity, as desired in high antibody concentration solutions, by adding non-ionic excipients, without changing other desired features, such as non-opalescence. Examples of non-ionizable excipients which may be added to the aqueous formulation of the present disclosure for altering desired characteristics of the formulation include, but are not limited to, mannitol, sorbitol, a nonionic surfactant (e.g., polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 80), sucrose, trehalose, raffinose, and maltose.Amino Acids

[0116] Amino acids can act as tonicity agents, protein stabilizers, antioxidants, and viscosity reducing agents in antibody formulations.

[0117] In some embodiments of the invention, a formulation comprises one or more amino acids. In some embodiments, a formulation comprises a basic amino acid. In some embodiments, a formulation comprises an acidic amino acid. In some embodiment, a formulation comprises a non-polar amino acid.

[0118] In some embodiments, an amino acid is present in the formulation at a concentration of 10-500 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 10-300 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 25-250 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 50-150 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 25-75 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 10 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 15 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 20 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 25 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 30 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 35 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 40 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 45 mM. In some embodiments, an amino acid is present inthe formulation at a concentration of 50 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 55 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 60 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 65 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 70 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 75 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 80 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 85 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 90 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 95 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 100 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 110 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 120 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 125 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 130 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 140 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 150 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 160 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 170 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 175 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 180 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 190 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 200 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 225 mM. In some embodiments, an amino acid is present in the formulation at a concentration of 250 mM.

[0119] In some embodiments, an amino acid is present in the formulation at a concentration of less than 150 mM. In some embodiments, an amino acid is present in the formulation at a concentration of less than 125 mM. In some embodiments, an amino acid is present in the formulation at a concentration of less than 120 mM. In some embodiments, an amino acid is present in the formulation at a concentration of less than 110 mM. In some embodiments, an amino acid is present in the formulation at a concentration of less than 100mM. In some embodiments, an amino acid is present in the formulation at a concentration of less than 90 mM. In some embodiments, an amino acid is present in the formulation at a concentration of less than 80 mM. In some embodiments, an amino acid is present in the formulation at a concentration of less than 75 mM. In some embodiments, an amino acid is present in the formulation at a concentration of less than 70 mM. In some embodiments, an amino acid is present in the formulation at a concentration of less than 65 mM. In some embodiments, an amino acid is present in the formulation at a concentration of less than 60 mM. In some embodiments, an amino acid is present in the formulation at a concentration of less than 55 mM. In some embodiments, an amino acid is present in the formulation at a concentration of less than 50 mM. In some embodiments, an amino acid is present in the formulation at a concentration of less than 40 mM. In some embodiments, an amino acid is present in the formulation at a concentration of less than 30 mM. In some embodiments, an amino acid is present in the formulation at a concentration of less than 25 mM.

[0120] In some embodiments of the invention, a formulation comprises one or more amino acids. It is contemplated that the one or more amino acids in the formulation, individually or combined, are typically present in a concentration of 10 mM to 300 mM. In some embodiments, the one or more amino acids in the formulation, individually or combined, are present at a concentration of 10 mM to 250 mM. In some embodiments, the one or more amino acids in the formulation, individually or combined, are present at a concentration of 10 mM to 225 mM. In some embodiments, the one or more amino acids in the formulation, individually or combined, are present at a concentration of 10 mM to 200 mM. In some embodiments, the one or more amino acids in the formulation, individually or combined, are present at a concentration of 10 mM to 175 mM. In some embodiments, the one or more amino acids in the formulation, individually or combined, are present at a concentration of 10 mM to 150 mM. In some embodiments, the one or more amino acids in the formulation, individually or combined, are present at a concentration of 10 mM to 125 mM. In some embodiments, the one or more amino acids in the formulation, individually or combined, are present at a concentration of 10 mM to 100 mM. In some embodiments, the one or more amino acids in the formulation, individually or combined, are present at a concentration of 10 mM to 75 mM. In some embodiments, the one or more amino acids in the formulation, individually or combined, are present at a concentration of 10 mM to 50 mM. In some embodiments, the one or more amino acids in the formulation, individually or combined, are present at a concentration of 10 mM to 25 mM. In some embodiments, the oneor more amino acids in the formulation, individually or combined, are present at a concentration of 20 mM to 250 mM. In some embodiments, the one or more amino acids in the formulation, individually or combined, are present at a concentration of 25 mM to 250 mM. In some embodiments, the one or more amino acids in the formulation, individually or combined, are present at a concentration of 50 mM to 250 mM. In some embodiments, the one or more amino acids in the formulation, individually or combined, are present at a concentration of 75 mM to 250 mM. In some embodiments, the one or more amino acids in the formulation, individually or combined, are present at a concentration of 100 mM to 250 mM. In some embodiments, the one or more amino acids in the formulation, individually or combined, are present at a concentration of 125 mM to 250 mM. In some embodiments, the one or more amino acids in the formulation, individually or combined, are present at a concentration of 150 mM to 250 mM. In some embodiments, the one or more amino acids in the formulation, individually or combined, are present at a concentration of 175 mM to 250 mM. In some embodiments, the one or more amino acids in the formulation, individually or combined, are present at a concentration of 200 mM to 250 mM. In some embodiments, the one or more amino acids in the formulation, individually or combined, are present at a concentration of 5 mM to 35 mM, of 10 mM to 35 mM, or of 15 mM to 30 mM.Basic Amino Acid

[0121] In some embodiments, a formulation comprises a basic amino acid. In some embodiments, a basic amino acid is lysine. In some embodiments, a basic amino acid is arginine. In some embodiments, a basic amino acid is histidine.

[0122] In some embodiments, arginine is L-arginine. In some embodiments, arginine is D-arginine. In some embodiments, arginine is arginine-HCl.

[0123] Arginine is a frequently used amino acid in antibody formulations to enhance protein refolding and to reduce protein-protein interaction and aggregation. Arginine is also used to reduce viscosity of high concentration antibody formulations. As such, it is desirable to use arginine at high concentration to prevent aggregation while reducing viscosity of antibody formulations. In fact, several antibody formulations use arginine at a high concentration, such as at 31.6 mg / ml Arg-HCl (150 mM) and at 26.1 mg / ml L-Arg (150 mM) in ADUHELM® and ENSPRYNG® formulations, respectively. The present invention is, in part, based on the surprising determination that the anti-ILlRl antibody is susceptible to aggregation in formulations comprising higher concentrations of arginine. Accordingly, oneaspect of the invention is a stable formulation for an anti-ILlRl antibody that comprises arginine at a concentration of less than about 130 mM (e.g., < 130 mM) with high stability and low viscosity.

[0124] In some embodiments, a basic amino acid is present in the formulation at a concentration of 10-500 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 10-300 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 25-250 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 50-150 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 50-100 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 25-75 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 50-75 mM.

[0125] In some embodiments, a basic amino acid is present in the formulation at a concentration of 10 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 15 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 20 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 25 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 30 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 35 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 40 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 45 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 50 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 55 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 60 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 65 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 70 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 75 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 80 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 85 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 90 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 95 mM. In some embodiments, abasic amino acid is present in the formulation at a concentration of 100 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 110 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 120 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 125 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 130 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 140 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 150 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 160 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 170 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 175 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 180 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 190 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 200 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 225 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of 250 mM. In some embodiments, a formulation is substantially free of a basic amino acid.

[0126] In some embodiments, a basic amino acid is present in the formulation at a concentration of less than 150 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of less than 125 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of less than 120 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of less than 110 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of less than 100 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of less than 90 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of less than 80 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of less than 75 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of less than 70 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of less than 65 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of less than 60 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of less than 55 mM. In someembodiments, a basic amino acid is present in the formulation at a concentration of less than 50 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of less than 40 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of less than 30 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of less than 25 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of less than 20 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of less than 15 mM. In some embodiments, a basic amino acid is present in the formulation at a concentration of less than 10 mM.

[0127] In some embodiments, arginine is present in the formulation at a concentration of less than 150 mM. In some embodiments, arginine is present in the formulation at a concentration of less than 140 mM. In some embodiments, arginine is present in the formulation at a concentration of less than 130 mM. In some embodiments, arginine is present in the formulation at a concentration of less than 125 mM. In some embodiments, arginine is present in the formulation at a concentration of less than 120 mM. In some embodiments, arginine is present in the formulation at a concentration of less than 110 mM. In some embodiments, arginine is present in the formulation at a concentration of less than 100 mM. In some embodiments, arginine acid is present in the formulation at a concentration of less than 90 mM. In some embodiments, an arginine is present in the formulation at a concentration of less than 80 mM. In some embodiments, arginine is present in the formulation at a concentration of less than 75 mM. In some embodiments, arginine is present in the formulation at a concentration of less than 70 mM. In some embodiments, arginine is present in the formulation at a concentration of less than 65 mM. In some embodiments, arginine is present in the formulation at a concentration of less than 60 mM. In some embodiments, arginine is present in the formulation at a concentration of less than 55 mM. In some embodiments, arginine is present in the formulation at a concentration of less than 50 mM. In some embodiments, arginine is present in the formulation at a concentration of less than 40 mM. In some embodiments, arginine is present in the formulation at a concentration of less than 30 mM. In some embodiments, arginine is present in the formulation at a concentration of less than 25 mM. In some embodiments, arginine is present in the formulation at a concentration of less than 20 mM. In some embodiments, arginine is present in the formulation at a concentration of less than 15 mM. In some embodiments, arginine ispresent in the formulation at a concentration of less thanlO mM. In some embodiments, a formulation is substantially free of arginine.

[0128] In some embodiments, arginine is present in the formulation at a concentration of 20-150 mM. In some embodiments, arginine is present in the formulation at a concentration of 25-125 mM. In some embodiments, arginine is present in the formulation at a concentration of 30-100 mM. In some embodiments, arginine is present in the formulation at a concentration of 50-75 mM. In some embodiments, arginine is present in the formulation at a concentration of 50-100 mM. In some embodiments, arginine is present in the formulation at a concentration of 50-70 mM. In some embodiments, arginine is present in the formulation at a concentration of 25-80 mM.

[0129] In some embodiments, arginine is present in the formulation at a concentration of 150 mM. In some embodiments, arginine is present in the formulation at a concentration of 125 mM. In some embodiments, arginine is present in the formulation at a concentration of 120 mM. In some embodiments, arginine is present in the formulation at a concentration of 110 mM. In some embodiments, arginine is present in the formulation at a concentration of 100 mM. In some embodiments, arginine acid is present in the formulation at a concentration of 90 mM. In some embodiments, an arginine is present in the formulation at a concentration of 80 mM. In some embodiments, arginine is present in the formulation at a concentration of 75 mM. In some embodiments, arginine is present in the formulation at a concentration of 70 mM. In some embodiments, arginine is present in the formulation at a concentration of 69 mM. In some embodiments, arginine is present in the formulation at a concentration of 68 mM. In some embodiments, arginine is present in the formulation at a concentration of 67 mM. In some embodiments, arginine is present in the formulation at a concentration of 66 mM. In some embodiments, arginine is present in the formulation at a concentration of 65 mM. In some embodiments, arginine is present in the formulation at a concentration of 64 mM. In some embodiments, arginine is present in the formulation at a concentration of 63 mM. In some embodiments, arginine is present in the formulation at a concentration of 62 mM. In some embodiments, arginine is present in the formulation at a concentration of 61 mM. In some embodiments, arginine is present in the formulation at a concentration of 60 mM. In some embodiments, arginine is present in the formulation at a concentration of 55 mM. In some embodiments, arginine is present in the formulation at a concentration of 50 mM. In some embodiments, arginine is present in the formulation at a concentration of 40 mM. In some embodiments, arginine is present in the formulation at a concentration of 30mM. In some embodiments, arginine is present in the formulation at a concentration of 25 mM. In some embodiments, arginine is present in the formulation at a concentration of 20 mM. In some embodiments, arginine is present in the formulation at a concentration of 15 mM. In some embodiments, arginine is present in the formulation at a concentration of 10 mM.

[0130] In some embodiments, lysine is present in the formulation at a concentration of 5-300 mM. In some embodiments, lysine is present in the formulation at a concentration of 10-250 mM. In some embodiments, lysine is present in the formulation at a concentration of 20-150 mM. In some embodiments, lysine is present in the formulation at a concentration of 25-125 mM. In some embodiments, lysine is present in the formulation at a concentration of 30- 100 mM. In some embodiments, lysine is present in the formulation at a concentration of 50-75 mM. In some embodiments, lysine is present in the formulation at a concentration of 25-80 mM.

[0131] In some embodiments, lysine is present in the formulation at a concentration of 150 mM. In some embodiments, lysine is present in the formulation at a concentration of 125 mM. In some embodiments, lysine is present in the formulation at a concentration of 120 mM. In some embodiments, lysine is present in the formulation at a concentration of 110 mM. In some embodiments, lysine is present in the formulation at a concentration of 100 mM. In some embodiments, lysine acid is present in the formulation at a concentration of 90 mM. In some embodiments, lysine is present in the formulation at a concentration of 80 mM. In some embodiments, lysine is present in the formulation at a concentration of 75 mM. In some embodiments, lysine is present in the formulation at a concentration of 70 mM. In some embodiments, lysine is present in the formulation at a concentration of 65 mM. In some embodiments, lysine is present in the formulation at a concentration of 60 mM. In some embodiments, lysine is present in the formulation at a concentration of 55 mM. In some embodiments, lysine is present in the formulation at a concentration of 50 mM. In some embodiments, lysine is present in the formulation at a concentration of 40 mM. In some embodiments, lysine is present in the formulation at a concentration of 30 mM. In some embodiments, lysine is present in the formulation at a concentration of 25 mM. In some embodiments, lysine is present in the formulation at a concentration of 20 mM. In some embodiments, lysine is present in the formulation at a concentration of 15 mM. In some embodiments, lysine is present in the formulation at a concentration of 10 mM.

[0132] In some embodiments, lysine is present in the formulation at a concentration of less than 150 mM. In some embodiments, lysine is present in the formulation at a concentration of less than 125 mM. In some embodiments, lysine is present in the formulation at a concentration of less than 120 mM. In some embodiments, lysine is present in the formulation at a concentration of less than 110 mM. In some embodiments, lysine is present in the formulation at a concentration of less than 100 mM. In some embodiments, lysine acid is present in the formulation at a concentration of less than 90 mM. In some embodiments, lysine is present in the formulation at a concentration of less than 80 mM. In some embodiments, lysine is present in the formulation at a concentration of less than 75 mM. In some embodiments, lysine is present in the formulation at a concentration of less than 70 mM. In some embodiments, lysine is present in the formulation at a concentration of less than 65 mM. In some embodiments, lysine is present in the formulation at a concentration of less than 60 mM. In some embodiments, lysine is present in the formulation at a concentration of less than 55 mM. In some embodiments, lysine is present in the formulation at a concentration of less than 50 mM. In some embodiments, lysine is present in the formulation at a concentration of less than 40 mM. In some embodiments, lysine is present in the formulation at a concentration of less than 30 mM. In some embodiments, lysine is present in the formulation at a concentration of less than 25 mM. In some embodiments, a formulation is substantially free of lysine.

[0133] In some embodiments, histidine is present in the formulation at a concentration of 5-300 mM. In some embodiments, histidine is present in the formulation at a concentration of 10-250 mM. In some embodiments, histidine is present in the formulation at a concentration of 20-150 mM. In some embodiments, histidine is present in the formulation at a concentration of 25-125 mM. In some embodiments, histidine is present in the formulation at a concentration of 30-100 mM. In some embodiments, histidine is present in the formulation at a concentration of 50-75 mM. In some embodiments, histidine is present in the formulation at a concentration of 50-100 mM. In some embodiments, histidine is present in the formulation at a concentration of 25-80 mM.

[0134] In some embodiments, histidine is present in the formulation at a concentration of 150 mM. In some embodiments, histidine is present in the formulation at a concentration of 125 mM. In some embodiments, histidine is present in the formulation at a concentration of 120 mM. In some embodiments, histidine is present in the formulation at a concentration of 110 mM. In some embodiments, histidine is present in the formulation at aconcentration of 100 mM. In some embodiments, histidine acid is present in the formulation at a concentration of 90 mM. In some embodiments, histidine is present in the formulation at a concentration of 80 mM. In some embodiments, histidine is present in the formulation at a concentration of 75 mM. In some embodiments, histidine is present in the formulation at a concentration of 70 mM. In some embodiments, histidine is present in the formulation at a concentration of 65 mM. In some embodiments, histidine is present in the formulation at a concentration of 60 mM. In some embodiments, histidine is present in the formulation at a concentration of 55 mM. In some embodiments, histidine is present in the formulation at a concentration of 50 mM. In some embodiments, histidine is present in the formulation at a concentration of 40 mM. In some embodiments, histidine is present in the formulation at a concentration of 30 mM. In some embodiments, histidine is present in the formulation at a concentration of 25 mM. In some embodiments, histidine is present in the formulation at a concentration of 20 mM. In some embodiments, histidine is present in the formulation at a concentration of 15 mM. In some embodiments, histidine is present in the formulation at a concentration of 10 mM. In some embodiments, a formulation is substantially free of histidine.

[0135] In some embodiments, histidine is present in the formulation at a concentration of less than 150 mM. In some embodiments, histidine is present in the formulation at a concentration of less than 125 mM. In some embodiments, histidine is present in the formulation at a concentration of less than 120 mM. In some embodiments, histidine is present in the formulation at a concentration of less than 110 mM. In some embodiments, histidine is present in the formulation at a concentration of less than 100 mM. In some embodiments, histidine acid is present in the formulation at a concentration of less than 90 mM. In some embodiments, histidine is present in the formulation at a concentration of less than 80 mM. In some embodiments, histidine is present in the formulation at a concentration of less than 75 mM. In some embodiments, histidine is present in the formulation at a concentration of less than 70 mM. In some embodiments, histidine is present in the formulation at a concentration of less than 65 mM. In some embodiments, histidine is present in the formulation at a concentration of less than 60 mM. In some embodiments, histidine is present in the formulation at a concentration of less than 55 mM. In some embodiments, histidine is present in the formulation at a concentration of less than 50 mM. In some embodiments, histidine is present in the formulation at a concentration of less than 40 mM. In some embodiments, histidine is present in the formulation at aconcentration of less than 30 mM. In some embodiments, histidine is present in the formulation at a concentration of less than 25 mM. In some embodiments, a formulation is substantially free of histidine.Acidic Amino Acid

[0136] In some embodiments, a formulation comprises an acidic amino acid. In some embodiments, an acidic amino acid is glutamate. In some embodiments, an acidic amino acid is aspartate.

[0137] In some embodiments, an acidic amino acid is present in the formulation at a concentration of 10-500 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 10-300 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 25-250 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 50-150 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 50-100 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 25-75 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 50-75 mM.

[0138] In some embodiments, an acidic amino acid is present in the formulation at a concentration of 10 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 15 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 20 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 25 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 30 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 35 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 40 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 45 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 50 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 55 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 60 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 65 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 70 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of75 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 80 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 85 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 90 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 95 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 100 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 110 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 120 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 125 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 130 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 140 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 150 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 160 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 170 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 175 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 180 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 190 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 200 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 225 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of 250 mM. In some embodiments, a formulation is substantially free of an acidic amino acid.

[0139] In some embodiments, an acidic amino acid is present in the formulation at a concentration of less than 150 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of less than 125 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of less than 120 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of less than 110 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of less than 100 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of less than 90 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of less than 80 mM. In someembodiments, an acidic amino acid is present in the formulation at a concentration of less than 75 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of less than 70 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of less than 65 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of less than 60 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of less than 55 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of less than 50 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of less than 40 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of less than 30 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of less than 25 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of less than 20 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of less than 15 mM. In some embodiments, an acidic amino acid is present in the formulation at a concentration of less than 10 mM.

[0140] In some embodiments, glutamate is present in the formulation at a concentration of 5-300 mM. In some embodiments, glutamate is present in the formulation at a concentration of 10-250 mM. In some embodiments, glutamate is present in the formulation at a concentration of 20-150 mM. In some embodiments, glutamate is present in the formulation at a concentration of 25-125 mM. In some embodiments, glutamate is present in the formulation at a concentration of 30-100 mM. In some embodiments, glutamate is present in the formulation at a concentration of 50-75 mM. In some embodiments, glutamate is present in the formulation at a concentration of 50-100 mM. In some embodiments, glutamate is present in the formulation at a concentration of 25-80 mM.

[0141] In some embodiments, glutamate is present in the formulation at a concentration of 150 mM. In some embodiments, glutamate is present in the formulation at a concentration of 125 mM. In some embodiments, glutamate is present in the formulation at a concentration of 120 mM. In some embodiments, glutamate is present in the formulation at a concentration of 110 mM. In some embodiments, glutamate is present in the formulation at a concentration of 100 mM. In some embodiments, glutamate is present in the formulation at a concentration of 90 mM. In some embodiments, glutamate is present in the formulation at a concentration of 80 mM. In some embodiments, glutamate is present in the formulation at a concentration of 75 mM. In some embodiments, glutamate is present in the formulation at aconcentration of 70 mM. In some embodiments, glutamate is present in the formulation at a concentration of 65 mM. In some embodiments, glutamate is present in the formulation at a concentration of 60 mM. In some embodiments, glutamate is present in the formulation at a concentration of 55 mM. In some embodiments, glutamate is present in the formulation at a concentration of 50 mM. In some embodiments, glutamate is present in the formulation at a concentration of 40 mM. In some embodiments, glutamate is present in the formulation at a concentration of 30 mM. In some embodiments, glutamate is present in the formulation at a concentration of 25 mM. In some embodiments, glutamate is present in the formulation at a concentration of 20 mM. In some embodiments, glutamate is present in the formulation at a concentration of 15 mM. In some embodiments, glutamate is present in the formulation at a concentration of 10 mM. In some embodiments, a formulation is substantially free of glutamate.

[0142] In some embodiments, glutamate is present in the formulation at a concentration of less than 150 mM. In some embodiments, glutamate is present in the formulation at a concentration of less than 125 mM. In some embodiments, glutamate is present in the formulation at a concentration of less than 120 mM. In some embodiments, glutamate is present in the formulation at a concentration of less than 110 mM. In some embodiments, glutamate is present in the formulation at a concentration of less than 100 mM. In some embodiments, glutamate acid is present in the formulation at a concentration of less than 90 mM. In some embodiments, glutamate is present in the formulation at a concentration of less than 80 mM. In some embodiments, glutamate is present in the formulation at a concentration of less than 75 mM. In some embodiments, glutamate is present in the formulation at a concentration of less than 70 mM. In some embodiments, glutamate is present in the formulation at a concentration of less than 65 mM. In some embodiments, glutamate is present in the formulation at a concentration of less than 60 mM. In some embodiments, glutamate is present in the formulation at a concentration of less than 55 mM. In some embodiments, glutamate is present in the formulation at a concentration of less than 50 mM. In some embodiments, glutamate is present in the formulation at a concentration of less than 40 mM. In some embodiments, glutamate is present in the formulation at a concentration of less than 30 mM. In some embodiments, glutamate is present in the formulation at a concentration of less than 25 mM. In some embodiments, glutamate is present in the formulation at a concentration of less than 20 mM. In some embodiments, glutamate is present in the formulation at a concentration of less than 15 mM.In some embodiments, glutamate is present in the formulation at a concentration of less than 10 mM.

[0143] In some embodiments, aspartate is present in the formulation at a concentration of 5-300 mM. In some embodiments, aspartate is present in the formulation at a concentration of 10-250 mM. In some embodiments, aspartate is present in the formulation at a concentration of 20-150 mM. In some embodiments, aspartate is present in the formulation at a concentration of 25-125 mM. In some embodiments, aspartate is present in the formulation at a concentration of 30-100 mM. In some embodiments, aspartate is present in the formulation at a concentration of 50-75 mM. In some embodiments, aspartate is present in the formulation at a concentration of 50-100 mM. In some embodiments, aspartate is present in the formulation at a concentration of 25-80 mM.

[0144] In some embodiments, aspartate is present in the formulation at a concentration of 150 mM. In some embodiments, aspartate is present in the formulation at a concentration of 125 mM. In some embodiments, aspartate is present in the formulation at a concentration of 120 mM. In some embodiments, aspartate is present in the formulation at a concentration of 110 mM. In some embodiments, aspartate is present in the formulation at a concentration of 100 mM. In some embodiments, aspartate is present in the formulation at a concentration of 90 mM. In some embodiments, aspartate is present in the formulation at a concentration of 80 mM. In some embodiments, aspartate is present in the formulation at a concentration of 75 mM. In some embodiments, aspartate is present in the formulation at a concentration of 70 mM. In some embodiments, aspartate is present in the formulation at a concentration of 65 mM. In some embodiments, aspartate is present in the formulation at a concentration of 60 mM. In some embodiments, aspartate is present in the formulation at a concentration of 55 mM. In some embodiments, aspartate is present in the formulation at a concentration of 50 mM. In some embodiments, aspartate is present in the formulation at a concentration of 40 mM. In some embodiments, aspartate is present in the formulation at a concentration of 30 mM. In some embodiments, aspartate is present in the formulation at a concentration of 25 mM. In some embodiments, aspartate is present in the formulation at a concentration of 20 mM. In some embodiments, aspartate is present in the formulation at a concentration of 15 mM. In some embodiments, aspartate is present in the formulation at a concentration of 10 mM. In some embodiments, a formulation is substantially free of aspartate.

[0145] In some embodiments, aspartate is present in the formulation at a concentration of less than 150 mM. In some embodiments, aspartate is present in the formulation at a concentration of less than 125 mM. In some embodiments, aspartate is present in the formulation at a concentration of less than 120 mM. In some embodiments, aspartate is present in the formulation at a concentration of less than 110 mM. In some embodiments, aspartate is present in the formulation at a concentration of less than 100 mM. In some embodiments, aspartate acid is present in the formulation at a concentration of less than 90 mM. In some embodiments, aspartate is present in the formulation at a concentration of less than 80 mM. In some embodiments, aspartate is present in the formulation at a concentration of less than 75 mM. In some embodiments, aspartate is present in the formulation at a concentration of less than 70 mM. In some embodiments, aspartate is present in the formulation at a concentration of less than 65 mM. In some embodiments, aspartate is present in the formulation at a concentration of less than 60 mM. In some embodiments, aspartate is present in the formulation at a concentration of less than 55 mM. In some embodiments, aspartate is present in the formulation at a concentration of less than 50 mM. In some embodiments, aspartate is present in the formulation at a concentration of less than 40 mM. In some embodiments, aspartate is present in the formulation at a concentration of less than 30 mM. In some embodiments, aspartate is present in the formulation at a concentration of less than 25 mM. In some embodiments, aspartate is present in the formulation at a concentration of less than 20 mM. In some embodiments, aspartate is present in the formulation at a concentration of less than 15 mM. In some embodiments, aspartate is present in the formulation at a concentration of less than 10 mM.Other Amino Acids

[0146] In some embodiments, a formulation comprises proline. In some embodiments, a formulation comprises methionine. In some embodiments, a formulation comprises glycine. In some embodiments, a formulation comprises asparagine.

[0147] In some embodiments, proline is present in the formulation at a concentration of 5-300 mM. In some embodiments, proline is present in the formulation at a concentration of 10-250 mM. In some embodiments, proline is present in the formulation at a concentration of 50-250 mM. In some embodiments, proline is present in the formulation at a concentration of 75-225 mM. In some embodiments, proline is present in the formulation at a concentration of 20-150 mM. In some embodiments, proline is present in the formulationat a concentration of 25-125 mM. In some embodiments, proline is present in the formulation at a concentration of 30-100 mM. In some embodiments, proline is present in the formulation at a concentration of 50-75 mM. In some embodiments, proline is present in the formulation at a concentration of 50-100 mM. In some embodiments, proline is present in the formulation at a concentration of 25-80 mM.

[0148] In some embodiments, proline is present in the formulation at a concentration of 150 mM. In some embodiments, proline is present in the formulation at a concentration of 125 mM. In some embodiments, proline is present in the formulation at a concentration of 120 mM. In some embodiments, proline is present in the formulation at a concentration of 110 mM. In some embodiments, proline is present in the formulation at a concentration of 100 mM. In some embodiments, proline acid is present in the formulation at a concentration of 90 mM. In some embodiments, proline is present in the formulation at a concentration of 80 mM. In some embodiments, proline is present in the formulation at a concentration of 75 mM. In some embodiments, proline is present in the formulation at a concentration of 70 mM. In some embodiments, proline is present in the formulation at a concentration of 65 mM. In some embodiments, proline is present in the formulation at a concentration of 60 mM. In some embodiments, proline is present in the formulation at a concentration of 55 mM. In some embodiments, proline is present in the formulation at a concentration of 50 mM. In some embodiments, proline is present in the formulation at a concentration of 40 mM. In some embodiments, proline is present in the formulation at a concentration of 30 mM. In some embodiments, proline is present in the formulation at a concentration of 25 mM. In some embodiments, proline is present in the formulation at a concentration of 20 mM. In some embodiments, proline is present in the formulation at a concentration of 15 mM. In some embodiments, proline is present in the formulation at a concentration of 10 mM. In some embodiments, a formulation is substantially free of proline.

[0149] In some embodiments, proline is present in the formulation at a concentration of less than 150 mM. In some embodiments, proline is present in the formulation at a concentration of less than 125 mM. In some embodiments, proline is present in the formulation at a concentration of less than 120 mM. In some embodiments, proline is present in the formulation at a concentration of less than 110 mM. In some embodiments, proline is present in the formulation at a concentration of less than 100 mM. In some embodiments, proline acid is present in the formulation at a concentration of less than 90 mM. In some embodiments, proline is present in the formulation at a concentration of less than 80 mM. Insome embodiments, proline is present in the formulation at a concentration of less than 75 mM. In some embodiments, proline is present in the formulation at a concentration of less than 70 mM. In some embodiments, proline is present in the formulation at a concentration of less than 65 mM. In some embodiments, proline is present in the formulation at a concentration of less than 60 mM. In some embodiments, proline is present in the formulation at a concentration of less than 55 mM. In some embodiments, proline is present in the formulation at a concentration of less than 50 mM. In some embodiments, proline is present in the formulation at a concentration of less than 40 mM. In some embodiments, proline is present in the formulation at a concentration of less than 30 mM. In some embodiments, proline is present in the formulation at a concentration of less than 25 mM. In some embodiments, proline is present in the formulation at a concentration of less than 20 mM. In some embodiments, proline is present in the formulation at a concentration of less than 15 mM. In some embodiments, proline is present in the formulation at a concentration of less than 10 mM.

[0150] In some embodiments, methionine is present in the formulation at a concentration of 5-300 mM. In some embodiments, methionine is present in the formulation at a concentration of 10-250 mM. In some embodiments, methionine is present in the formulation at a concentration of 20-150 mM. In some embodiments, methionine is present in the formulation at a concentration of 25-125 mM. In some embodiments, methionine is present in the formulation at a concentration of 30-100 mM. In some embodiments, methionine is present in the formulation at a concentration of 50-75 mM. In some embodiments, aspartate is present in the formulation at a concentration of 50-100 mM. In some embodiments, methionine is present in the formulation at a concentration of 25-80 mM.

[0151] In some embodiments, methionine is present in the formulation at a concentration of 150 mM. In some embodiments, methionine is present in the formulation at a concentration of 125 mM. In some embodiments, methionine is present in the formulation at a concentration of 120 mM. In some embodiments, methionine is present in the formulation at a concentration of 110 mM. In some embodiments, methionine is present in the formulation at a concentration of 100 mM. In some embodiments, methionine acid is present in the formulation at a concentration of 90 mM. In some embodiments, methionine is present in the formulation at a concentration of 80 mM. In some embodiments, methionine is present in the formulation at a concentration of 75 mM. In some embodiments, methionine is present in the formulation at a concentration of less than 70 mM. In some embodiments,methionine is present in the formulation at a concentration of less than 65 mM. In some embodiments, methionine is present in the formulation at a concentration of less than 60 mM. In some embodiments, methionine is present in the formulation at a concentration of less than 55 mM. In some embodiments, methionine is present in the formulation at a concentration of 50 mM. In some embodiments, methionine is present in the formulation at a concentration of40 mM. In some embodiments, methionine is present in the formulation at a concentration of30 mM. In some embodiments, methionine is present in the formulation at a concentration of 25 mM. In some embodiments, methionine is present in the formulation at a concentration of20 mM. In some embodiments, methionine is present in the formulation at a concentration of15 mM. In some embodiments, methionine is present in the formulation at a concentration of 10 mM. In some embodiments, a formulation is substantially free of methionine.

[0152] In some embodiments, glycine is present in the formulation at a concentration of 5-300 mM. In some embodiments, glycine is present in the formulation at a concentration of 10-250 mM. In some embodiments, glycine is present in the formulation at a concentration of 20-150 mM. In some embodiments, glycine is present in the formulation at a concentration of 25-125 mM. In some embodiments, glycine is present in the formulation at a concentration of 30-100 mM. In some embodiments, glycine is present in the formulation at a concentration of 50-75 mM. In some embodiments, aspartate is present in the formulation at a concentration of 50-100 mM. In some embodiments, glycine is present in the formulation at a concentration of 25-80 mM.

[0153] In some embodiments, glycine is present in the formulation at a concentration of 150 mM. In some embodiments, glycine is present in the formulation at a concentration of 125 mM. In some embodiments, glycine is present in the formulation at a concentration of 120 mM. In some embodiments, glycine is present in the formulation at a concentration of 110 mM. In some embodiments, glycine is present in the formulation at a concentration of 100 mM. In some embodiments, glycine acid is present in the formulation at a concentration of 90 mM. In some embodiments, glycine is present in the formulation at a concentration of 80 mM. In some embodiments, glycine is present in the formulation at a concentration of 75 mM. In some embodiments, glycine is present in the formulation at a concentration of less than 70 mM. In some embodiments, glycine is present in the formulation at a concentration of less than 65 mM. In some embodiments, glycine is present in the formulation at a concentration of less than 60 mM. In some embodiments, glycine is present in the formulation at a concentration of less than 55 mM. In some embodiments, glycine is presentin the formulation at a concentration of 50 mM. In some embodiments, glycine is present in the formulation at a concentration of 40 mM. In some embodiments, glycine is present in the formulation at a concentration of 30 mM. In some embodiments, glycine is present in the formulation at a concentration of 25 mM. In some embodiments, glycine is present in the formulation at a concentration of 20 mM. In some embodiments, glycine is present in the formulation at a concentration of 15 mM. In some embodiments, glycine is present in the formulation at a concentration of 10 mM. In some embodiments, a formulation is substantially free of glycine.

[0154] In some embodiments, asparagine is present in the formulation at a concentration of 5-300 mM. In some embodiments, asparagine is present in the formulation at a concentration of 10-250 mM. In some embodiments, asparagine is present in the formulation at a concentration of 20-150 mM. In some embodiments, asparagine is present in the formulation at a concentration of 25-125 mM. In some embodiments, asparagine is present in the formulation at a concentration of 30-100 mM. In some embodiments, asparagine is present in the formulation at a concentration of 50-75 mM. In some embodiments, asparagine is present in the formulation at a concentration of 50-100 mM. In some embodiments, asparagine is present in the formulation at a concentration of 25-80 mM.

[0155] In some embodiments, asparagine is present in the formulation at a concentration of 150 mM. In some embodiments, asparagine is present in the formulation at a concentration of 125 mM. In some embodiments, asparagine is present in the formulation at a concentration of 120 mM. In some embodiments, asparagine is present in the formulation at a concentration of 110 mM. In some embodiments, asparagine is present in the formulation at a concentration of 100 mM. In some embodiments, asparagine acid is present in the formulation at a concentration of 90 mM. In some embodiments, asparagine is present in the formulation at a concentration of 80 mM. In some embodiments, asparagine is present in the formulation at a concentration of 75 mM. In some embodiments, asparagine is present in the formulation at a concentration of 70 mM. In some embodiments, asparagine is present in the formulation at a concentration of 65 mM. In some embodiments, asparagine is present in the formulation at a concentration of 60 mM. In some embodiments, asparagine is present in the formulation at a concentration of 55 mM. In some embodiments, asparagine is present in the formulation at a concentration of 50 mM. In some embodiments, asparagine is present in the formulation at a concentration of 40 mM. In some embodiments, asparagine is present in the formulation at a concentration of 30 mM. In some embodiments, asparagine is presentin the formulation at a concentration of 25 mM. In some embodiments, asparagine is present in the formulation at a concentration of 20 mM. In some embodiments, asparagine is present in the formulation at a concentration of 15 mM. In some embodiments, asparagine is present in the formulation at a concentration of 10 mM. In some embodiments, a formulation is substantially free of asparagine.

[0156] In some embodiments, asparagine is present in the formulation at a concentration of less than 150 mM. In some embodiments, asparagine is present in the formulation at a concentration of less than 125 mM. In some embodiments, asparagine is present in the formulation at a concentration of less than 120 mM. In some embodiments, asparagine is present in the formulation at a concentration of less than 110 mM. In some embodiments, asparagine is present in the formulation at a concentration of less than 100 mM. In some embodiments, asparagine acid is present in the formulation at a concentration of less than 90 mM. In some embodiments, asparagine is present in the formulation at a concentration of less than 80 mM. In some embodiments, asparagine is present in the formulation at a concentration of less than 75 mM. In some embodiments, asparagine is present in the formulation at a concentration of less than 70 mM. In some embodiments, asparagine is present in the formulation at a concentration of less than 65 mM. In some embodiments, asparagine is present in the formulation at a concentration of less than 60 mM. In some embodiments, asparagine is present in the formulation at a concentration of less than 55 mM. In some embodiments, asparagine is present in the formulation at a concentration of less than 50 mM. In some embodiments, asparagine is present in the formulation at a concentration of less than 40 mM. In some embodiments, asparagine is present in the formulation at a concentration of less than 30 mM. In some embodiments, asparagine is present in the formulation at a concentration of less than 25 mM. In some embodiments, a formulation is substantially free of asparagine.Antibody Concentration

[0157] In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 50-200 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 50-195 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 50-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 50-185 mg / ml. In some embodiments, the stable formulationcomprises the anti-ILlRl antibody at a concentration of 50-180 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 50-175 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 50-170 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 50-165 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 50-160 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 50-155 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 50-150 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 50-125 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 50-100 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 50-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 55-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 60-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 65-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 70-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 75-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 80-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 85-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 90-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 95-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 100-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 105-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 110-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 115-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 120-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 125-190 mg / ml. In someembodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 130-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 135-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 140-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 145-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 150-190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 100-150 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 100-160 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 100-165 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 150-160 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 150-165 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 135 mg / mL to 165 mg / mL. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of 145 mg / mL to 160 mg / mL.

[0158] In some embodiments, the anti-ILlRl antibody is present at a concentration of 50 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 60 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 70 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 80 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 100 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 110 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 120 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 125 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 130 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 135 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 140 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 145 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 150 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 155 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 160 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 165mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 170 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 175 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 180 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 185 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 190 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 200 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 225 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 250 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 275 mg / mL. In some embodiments, the anti-ILlRl antibody is present at a concentration of 300 mg / mL.

[0159] In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 50 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 60 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 70 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 80 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 90 mg / ml. In some embodiments, the stable formulation comprises the anti- IL1R1 antibody at a concentration of greater than 100 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 110 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 120 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 125 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 130 mg / ml. In some embodiments, the stable formulation comprises the anti- IL1R1 antibody at a concentration of greater than 135 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 140 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 145 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 150 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 155 mg / ml. In some embodiments, the stable formulation comprises the anti-IL1R1 antibody at a concentration of greater than 160 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 165 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 170 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 175 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 180 mg / ml. In some embodiments, the stable formulation comprises the anti- IL1R1 antibody at a concentration of greater than 185 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 190 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 195 mg / ml. In some embodiments, the stable formulation comprises the anti-ILlRl antibody at a concentration of greater than 200 mg / ml.Buffers

[0160] In some embodiments of the invention, a formulation comprises a buffer to control pH. Suitable buffers include, for example, acetate, citrate, histidine, phosphate, succinate, tris(hydroxymethyl)aminomethane ("Tris") and other organic acids.

[0161] In some embodiments, the formulation comprises a buffer at a concentration ranging from 5 mM to 100 mM. In some embodiments, the formulation comprises a buffer at a concentration ranging from 5 mM to 75 mM. In some embodiments, the formulation comprises a buffer at a concentration ranging from 5 mM to 60 mM. In some embodiments, the formulation comprises a buffer at a concentration ranging from 25 mM to 50 mM. In some embodiments, the formulation comprises a buffer at a concentration ranging from 10 mM to 100 mM. In some embodiments, the formulation comprises a buffer at a concentration ranging from 20 mM to 100 mM. In some embodiments, the formulation comprises a buffer at a concentration ranging from 30 mM to 100 mM. In some embodiments, the formulation comprises a buffer at a concentration ranging from 40 mM to 100 mM. In some embodiments, the formulation comprises a buffer at a concentration ranging from 50 mM to 100 mM. In some embodiments, the formulation comprises a buffer at a concentration ranging from 75 mM to 100 mM. In some embodiments, the formulation comprises a buffer at a concentration ranging from 10 mM to 200 mM. In some embodiments, the formulation comprises a buffer at a concentration of 10 mM. In some embodiments, the formulation comprises a buffer at a concentration of 20 mM. In someembodiments, the formulation comprises a buffer at a concentration of 25 mM. In some embodiments, the formulation comprises a buffer at a concentration of 30 mM. In some embodiments, the formulation comprises a buffer at a concentration of 35 mM. In some embodiments, the formulation comprises a buffer at a concentration of 40 mM. In some embodiments, the formulation comprises a buffer at a concentration of 45 mM. In some embodiments, the formulation comprises a buffer at a concentration of 50 mM. In some embodiments, the formulation comprises a buffer at a concentration of 55 mM. In some embodiments, the formulation comprises a buffer at a concentration of 60 mM. In some embodiments, the formulation comprises a buffer at a concentration of 65 mM. In some embodiments, the formulation comprises a buffer at a concentration of 70 mM. In some embodiments, the formulation comprises a buffer at a concentration of 75 mM. In some embodiments, the formulation comprises a buffer at a concentration of 80 mM. In some embodiments, the formulation comprises a buffer at a concentration of 90 mM. In some embodiments, the formulation comprises a buffer at a concentration of 100 mM.

[0162] In some embodiments, the formulation comprises acetate. In some embodiments, the formulation comprises acetate at a concentration ranging from 5 mM to 100 mM. In some embodiments, the formulation comprises acetate at a concentration ranging from 5 mM to 90 mM. In some embodiments, the formulation comprises acetate at a concentration ranging from 15 mM to 80 mM. In some embodiments, the formulation comprises acetate at a concentration ranging from 20 mM to 75 mM. In some embodiments, the formulation comprises acetate at a concentration ranging from 25 mM to 50 mM. In some embodiments, the formulation comprises acetate at a concentration of 5 mM. In some embodiments, the formulation comprises acetate at a concentration of 10 mM. In some embodiments, the formulation comprises acetate at a concentration of 15 mM. In some embodiments, the formulation comprises acetate at a concentration of 20 mM. In some embodiments, the formulation comprises acetate at a concentration of 25 mM. In some embodiments, the formulation comprises acetate at a concentration of 30 mM. In some embodiments, the formulation comprises acetate at a concentration of 35 mM. In some embodiments, the formulation comprises acetate at a concentration of 40 mM. In some embodiments, the formulation comprises acetate at a concentration of 45 mM. In some embodiments, the formulation comprises acetate at a concentration of 50 mM. In some embodiments, the formulation comprises acetate at a concentration of 55 mM. In some embodiments, the formulation comprises acetate at a concentration of 60 mM. In someembodiments, the formulation comprises acetate at a concentration of 65 mM. In some embodiments, the formulation comprises acetate at a concentration of 70 mM. In some embodiments, the formulation comprises acetate at a concentration of 75 mM. In some embodiments, the formulation comprises acetate at a concentration of 80 mM. In some embodiments, the formulation comprises acetate at a concentration of 85 mM. In some embodiments, the formulation comprises acetate at a concentration of 90 mM. In some embodiments, the formulation comprises acetate at a concentration of 100 mM. In some embodiments the buffer is sodium acetate.

[0163] In some embodiments, the formulation comprises histidine. In some embodiments, the formulation comprises histidine at a concentration ranging from 5 mM to 100 mM. In some embodiments, the formulation comprises histidine at a concentration ranging from 5 mM to 90 mM. In some embodiments, the formulation comprises histidine at a concentration ranging from 15 mM to 80 mM. In some embodiments, the formulation comprises histidine at a concentration ranging from 20 mM to 75 mM. In some embodiments, the formulation comprises histidine at a concentration ranging from 25 mM to 50 mM. In some embodiments, the formulation comprises histidine at a concentration of 5 mM. In some embodiments, the formulation comprises histidine at a concentration of 10 mM. In some embodiments, the formulation comprises histidine at a concentration of 15 mM. In some embodiments, the formulation comprises histidine at a concentration of 20 mM. In some embodiments, the formulation comprises histidine at a concentration of 25 mM. In some embodiments, the formulation comprises histidine at a concentration of 30 mM. In some embodiments, the formulation comprises histidine at a concentration of 35 mM. In some embodiments, the formulation comprises histidine at a concentration of 40 mM. In some embodiments, the formulation comprises histidine at a concentration of 45 mM. In some embodiments, the formulation comprises histidine at a concentration of 50 mM. In some embodiments, the formulation comprises histidine at a concentration of 55 mM. In some embodiments, the formulation comprises histidine at a concentration of 60 mM. In some embodiments, the formulation comprises histidine at a concentration of 65 mM. In some embodiments, the formulation comprises histidine at a concentration of 70 mM. In some embodiments, the formulation comprises histidine at a concentration of 75 mM. In some embodiments, the formulation comprises histidine at a concentration of 80 mM. In some embodiments, the formulation comprises histidine at a concentration of 85 mM. In some embodiments, the formulation comprises histidine at a concentration of 90mM. In some embodiments, the formulation comprises histidine at a concentration of 100 mM.

[0164] In some embodiments, the formulation comprises succinate. In some embodiments, the formulation comprises succinate at a concentration ranging from 5 mM to 100 mM. In some embodiments, the formulation comprises succinate at a concentration ranging from 5 mM to 90 mM. In some embodiments, the formulation comprises succinate at a concentration ranging from 15 mM to 80 mM. In some embodiments, the formulation comprises succinate at a concentration ranging from 20 mM to 75 mM. In some embodiments, the formulation comprises succinate at a concentration ranging from 25 mM to 50 mM. In some embodiments, the formulation comprises succinate at a concentration of 5 mM. In some embodiments, the formulation comprises succinate at a concentration of 10 mM. In some embodiments, the formulation comprises succinate at a concentration of 15 mM. In some embodiments, the formulation comprises succinate at a concentration of 20 mM. In some embodiments, the formulation comprises succinate at a concentration of 25 mM. In some embodiments, the formulation comprises succinate at a concentration of 30 mM. In some embodiments, the formulation comprises succinate at a concentration of 35 mM. In some embodiments, the formulation comprises succinate at a concentration of 40 mM. In some embodiments, the formulation comprises succinate at a concentration of 45 mM. In some embodiments, the formulation comprises succinate at a concentration of 50 mM. In some embodiments, the formulation comprises succinate at a concentration of 55 mM. In some embodiments, the formulation comprises succinate at a concentration of 60 mM. In some embodiments, the formulation comprises succinate at a concentration of 65 mM. In some embodiments, the formulation comprises succinate at a concentration of 70 mM. In some embodiments, the formulation comprises succinate at a concentration of 75 mM. In some embodiments, the formulation comprises succinate at a concentration of 80 mM. In some embodiments, the formulation comprises succinate at a concentration of 85 mM. In some embodiments, the formulation comprises succinate at a concentration of 90 mM. In some embodiments, the formulation comprises succinate at a concentration of 100 mM.

[0165] In some embodiments, the formulation comprises phosphate. In some embodiments, the formulation comprises phosphate at a concentration ranging from 5 mM to 100 mM. In some embodiments, the formulation comprises phosphate at a concentration ranging from 5 mM to 90 mM. In some embodiments, the formulation comprises phosphateat a concentration ranging from 15 mM to 80 mM. In some embodiments, the formulation comprises phosphate at a concentration ranging from 20 mM to 75 mM. In some embodiments, the formulation comprises phosphate at a concentration ranging from 25 mM to 50 mM. In some embodiments, the formulation comprises phosphate at a concentration of 5 mM. In some embodiments, the formulation comprises phosphate at a concentration of 10 mM. In some embodiments, the formulation comprises phosphate at a concentration of 15 mM. In some embodiments, the formulation comprises phosphate at a concentration of 20 mM. In some embodiments, the formulation comprises phosphate at a concentration of 25 mM. In some embodiments, the formulation comprises phosphate at a concentration of 30 mM. In some embodiments, the formulation comprises phosphate at a concentration of 35 mM. In some embodiments, the formulation comprises phosphate at a concentration of 40 mM. In some embodiments, the formulation comprises phosphate at a concentration of 45 mM. In some embodiments, the formulation comprises phosphate at a concentration of 50 mM. In some embodiments, the formulation comprises phosphate at a concentration of 55 mM. In some embodiments, the formulation comprises phosphate at a concentration of 60 mM. In some embodiments, the formulation comprises phosphate at a concentration of 65 mM. In some embodiments, the formulation comprises phosphate at a concentration of 70 mM. In some embodiments, the formulation comprises phosphate at a concentration of 75 mM. In some embodiments, the formulation comprises phosphate at a concentration of 80 mM. In some embodiments, the formulation comprises phosphate at a concentration of 85 mM. In some embodiments, the formulation comprises phosphate at a concentration of 90 mM. In some embodiments, the formulation comprises phosphate at a concentration of 100 mM.

[0166] In some embodiments, the formulation comprises citrate. In some embodiments, the formulation comprises citrate at a concentration ranging from 5 mM to 100 mM. In some embodiments, the formulation comprises citrate at a concentration ranging from 5 mM to 90 mM. In some embodiments, the formulation comprises citrate at a concentration ranging from 15 mM to 80 mM. In some embodiments, the formulation comprises citrate at a concentration ranging from 20 mM to 75 mM. In some embodiments, the formulation comprises citrate at a concentration ranging from 25 mM to 50 mM. In some embodiments, the formulation comprises citrate at a concentration of 5 mM. In some embodiments, the formulation comprises citrate at a concentration of 10 mM. In some embodiments, the formulation comprises citrate at a concentration of 15 mM. In someembodiments, the formulation comprises citrate at a concentration of 20 mM. In some embodiments, the formulation comprises citrate at a concentration of 25 mM. In some embodiments, the formulation comprises citrate at a concentration of 30 mM. In some embodiments, the formulation comprises citrate at a concentration of 35 mM. In some embodiments, the formulation comprises citrate at a concentration of 40 mM. In some embodiments, the formulation comprises citrate at a concentration of 45 mM. In some embodiments, the formulation comprises citrate at a concentration of 50 mM. In some embodiments, the formulation comprises citrate at a concentration of 55 mM. In some embodiments, the formulation comprises citrate at a concentration of 60 mM. In some embodiments, the formulation comprises citrate at a concentration of 65 mM. In some embodiments, the formulation comprises citrate at a concentration of 70 mM. In some embodiments, the formulation comprises citrate at a concentration of 75 mM. In some embodiments, the formulation comprises citrate at a concentration of 80 mM. In some embodiments, the formulation comprises citrate at a concentration of 85 mM. In some embodiments, the formulation comprises citrate at a concentration of 90 mM. In some embodiments, the formulation comprises citrate at a concentration of 100 mM.

[0167] In some embodiments, the formulation comprises Tris. In some embodiments, the formulation comprises Tris at a concentration ranging from 5 mM to 100 mM. In some embodiments, the formulation comprises Tris at a concentration ranging from 5 mM to 90 mM. In some embodiments, the formulation comprises Tris at a concentration ranging from 15 mM to 80 mM. In some embodiments, the formulation comprises Tris at a concentration ranging from 20 mM to 75 mM. In some embodiments, the formulation comprises Tris at a concentration ranging from 25 mM to 50 mM. In some embodiments, the formulation comprises Tris at a concentration of 5 mM. In some embodiments, the formulation comprises Tris at a concentration of 10 mM. In some embodiments, the formulation comprises Tris at a concentration of 15 mM. In some embodiments, the formulation comprises Tris at a concentration of 20 mM. In some embodiments, the formulation comprises Tris at a concentration of 25 mM. In some embodiments, the formulation comprises Tris at a concentration of 30 mM. In some embodiments, the formulation comprises Tris at a concentration of 35 mM. In some embodiments, the formulation comprises Tris at a concentration of 40 mM. In some embodiments, the formulation comprises Tris at a concentration of 45 mM. In some embodiments, the formulation comprises Tris at a concentration of 50 mM. In some embodiments, the formulation comprises Tris at aconcentration of 55 mM. In some embodiments, the formulation comprises Tris at a concentration of 60 mM. In some embodiments, the formulation comprises Tris at a concentration of 65 mM. In some embodiments, the formulation comprises Tris at a concentration of 70 mM. In some embodiments, the formulation comprises Tris at a concentration of 75 mM. In some embodiments, the formulation comprises Tris at a concentration of 80 mM. In some embodiments, the formulation comprises Tris at a concentration of 85 mM. In some embodiments, the formulation comprises Tris at a concentration of 90 mM. In some embodiments, the formulation comprises Tris at a concentration of 100 mM. pH

[0168] When considering any antibody formulation, the pH range of the solution is vital to formulation since antibodies are stable against chemical modifications and aggregation over a narrow pH range. Stabilizing buffers for antibodies should be rationally selected, as reactions leading to physicochemical instability are primarily driven by pH and ionic strength of the buffer.

[0169] In some embodiments, a formulation comprises a pH of of 4.0 to 7.0. In some embodiments, a formulation comprises a pH of 4.0 to 7.4. In some embodiments, a formulation comprises a pH of 4.3 to 6.5. In some embodiments, a formulation comprises a pH of 4.5 to 6.1. In some embodiments, a formulation comprises a pH of 4.3 to 4.6. In some embodiments, a formulation comprises a pH of 4.5 to 5.5. In some embodiments, a formulation comprises a pH of 4.4 to 5.7. In some embodiments, a formulation comprises a pH of 4.4 to 5.4. In some embodiments, a formulation comprises a pH of 4.6 to 5.2. In some embodiments, a formulation comprises a pH of 4.7 to 5.1. In some embodiments, a formulation comprises a pH of 4.7 to 5.7. In some embodiments, a formulation comprises a pH of 5.0 to 5.4. In some embodiments, a formulation comprises a pH of 4.8 to 5.8. In some embodiments, a formulation comprises a pH of 4.5 to 5.0. In some embodiments, a formulation comprises a pH of 5.0 to 5.2. In some embodiments, a formulation comprises a pH of 5.0 to 5.6. In some embodiments, a formulation comprises a pH of 5.5 to 6.5. In some embodiments, a formulation comprises a pH of 5.2 to 6.2. In some embodiments, a formulation comprises a pH of 5.2 to 5.6. In some embodiments, a formulation comprises a pH of 4.9 to 5.2.

[0170] In some embodiments, a formulation comprises a pH of 4.0. In some embodiments, a formulation comprises a pH of 4.1. In some embodiments, a formulation comprises a pH of 4.2. In some embodiments, a formulation comprises a pH of 4.3. In some embodiments, a formulation comprises a pH of 4.4. In some embodiments, a formulation comprises a pH of 4.5. In some embodiments, a formulation comprises a pH of 4.6. In some embodiments, a formulation comprises a pH of 4.7. In some embodiments, a formulation comprises a pH of 4.8. In some embodiments, a formulation comprises a pH of 4.9. In some embodiments, a formulation comprises a pH of 5.0. In some embodiments, a formulation comprises a pH of 5.1. In some embodiments, a formulation comprises a pH of 5.2. In some embodiments, a formulation comprises a pH of 5.3. In some embodiments, a formulation comprises a pH of 5.4. In some embodiments, a formulation comprises a pH of 5.5. In some embodiments, a formulation comprises a pH of 5.6. In some embodiments, a formulation comprises a pH of 5.7. In some embodiments, a formulation comprises a pH of 5.8. In some embodiments, a formulation comprises a pH of 5.9. In some embodiments, a formulation comprises a pH of 6.0. In some embodiments, a formulation comprises a pH of 6.1. In some embodiments, a formulation comprises a pH of 6.2. In some embodiments, a formulation comprises a pH of 6.3. In some embodiments, a formulation comprises a pH of 6.4. In some embodiments, a formulation comprises a pH of 6.5. In some embodiments, a formulation comprises a pH of 6.6. In some embodiments, a formulation comprises a pH of 6.7. In some embodiments, a formulation comprises a pH of 6.8. In some embodiments, a formulation comprises a pH of 6.9. In some embodiments, a formulation comprises a pH of 7.0.

[0171] In some embodiments, a formulation comprises acetate and a pH of 4.0 to 5.6. In some embodiments, a formulation comprises acetate and a pH of 3.5 to 6.0. In some embodiments, a formulation comprises acetate and a pH of 3.8 to 5.8. In some embodiments, a formulation comprises acetate and a pH of 4.8 to 5.8. In some embodiments, a formulation comprises acetate and a pH of 4.0 to 5.8. In some embodiments, a formulation comprises acetate and a pH of 4.5 to 5.2. In some embodiments, a formulation comprises acetate and a pH of 4.4 to 5.7. In some embodiments, a formulation comprises acetate and a pH of 4.4 to 5.4. In some embodiments, a formulation comprises acetate and a pH of 4.6 to 5.2. In some embodiments, a formulation comprises acetate and a pH of 4.7 to 5.1. In some embodiments, a formulation comprises acetate and a pH of 4.7 to 5.7. In some embodiments, a formulation comprises acetate and a pH of 5.0 to 5.4. In some embodiments, a formulation comprises acetate and a pH of 4.9 to 5.2. In some embodiments, a formulation comprises acetate and apH of 4.0. In some embodiments, a formulation comprises acetate and a pH of 4.1. In some embodiments, a formulation comprises acetate and a pH of 4.2. In some embodiments, a formulation comprises acetate and a pH of 4.3. In some embodiments, a formulation comprises acetate and a pH of 4.4. In some embodiments, a formulation comprises acetate and a pH of 4.5. In some embodiments, a formulation comprises acetate and a pH of 4.6. In some embodiments, a formulation comprises acetate and a pH of 4.7. In some embodiments, a formulation comprises acetate and a pH of 4.8. In some embodiments, a formulation comprises acetate and a pH of 4.9. In some embodiments, a formulation comprises acetate and a pH of 5.0. In some embodiments, a formulation comprises acetate and a pH of 5.1. In some embodiments, a formulation comprises acetate and a pH of 5.2. In some embodiments, a formulation comprises acetate and a pH of 5.3. In some embodiments, a formulation comprises acetate and a pH of 5.4. In some embodiments, a formulation comprises acetate and a pH of 5.5. In some embodiments, a formulation comprises acetate and a pH of 5.6. In some embodiments, a formulation comprises acetate and a pH of 5.7.

[0172] In some embodiments, a formulation comprises succinate and a pH of 4.5 to 6.0. In some embodiments, a formulation comprises succinate and a pH of 3.0 to 7.0. In some embodiments, a formulation comprises succinate and a pH of 3.0 to 6.8. In some embodiments, a formulation comprises succinate and a pH of 3.2 to 6.6. In some embodiments, a formulation comprises succinate and a pH of 4.0 to 7.0. In some embodiments, a formulation comprises succinate and a pH of 5.0 to 5.8. In some embodiments, a formulation comprises succinate and a pH of 5.4 to 5.8. In some embodiments, a formulation comprises succinate and a pH of 4.4. In some embodiments, a formulation comprises succinate and a pH of 4.5. In some embodiments, a formulation comprises succinate and a pH of 4.6. In some embodiments, a formulation comprises succinate and a pH of 4.7. In some embodiments, a formulation comprises succinate and a pH of 4.8. In some embodiments, a formulation comprises succinate and a pH of 4.9. In some embodiments, a formulation comprises succinate and a pH of 5.0. In some embodiments, a formulation comprises succinate and a pH of 5.1. In some embodiments, a formulation comprises succinate and a pH of 5.2. In some embodiments, a formulation comprises succinate and a pH of 5.3. In some embodiments, a formulation comprises succinate and a pH of 5.4. In some embodiments, a formulation comprises succinate and a pH of 5.5. In some embodiments, a formulation comprises succinate and a pH of 5.6. In some embodiments, a formulation comprises succinate and a pH of 5.7. In some embodiments, aformulation comprises succinate and a pH of 5.8. In some embodiments, a formulation comprises succinate and a pH of 5.9. In some embodiments, a formulation comprises succinate and a pH of 6.0. In some embodiments, a formulation comprises succinate and a pH of 6.1. In some embodiments, a formulation comprises succinate and a pH of 6.2.

[0173] In some embodiments, a formulation comprises histidine and a pH of 5.3 to 7.5. In some embodiments, a formulation comprises histidine and a pH of 4.5 to 7.5. In some embodiments, a formulation comprises histidine and a pH of 5.0 to 7.0. In some embodiments, a formulation comprises histidine and a pH of 5.5 to 7.4. In some embodiments, a formulation comprises histidine and a pH of 5.8 to 6.3. In some embodiments, a formulation comprises histidine and a pH of 5.0. In some embodiments, a formulation comprises histidine and a pH of 5.1. In some embodiments, a formulation comprises histidine and a pH of 5.2. In some embodiments, a formulation comprises histidine and a pH of 5.3. In some embodiments, a formulation comprises histidine and a pH of 5.4. In some embodiments, a formulation comprises histidine and a pH of 5.5. In some embodiments, a formulation comprises histidine and a pH of 5.6. In some embodiments, a formulation comprises histidine and a pH of 5.7. In some embodiments, a formulation comprises histidine and a pH of 5.8. In some embodiments, a formulation comprises histidine and a pH of 5.9. In some embodiments, a formulation comprises histidine and a pH of 6.0. In some embodiments, a formulation comprises histidine and a pH of 6.1. In some embodiments, a formulation comprises histidine and a pH of 6.2. In some embodiments, a formulation comprises histidine and a pH of 6.3. In some embodiments, a formulation comprises histidine and a pH of 6.4. In some embodiments, a formulation comprises histidine and a pH of 6.5. In some embodiments, a formulation comprises histidine and a pH of 6.6. In some embodiments, a formulation comprises histidine and a pH of 6.7. In some embodiments, a formulation comprises histidine and a pH of 6.8. In some embodiments, a formulation comprises histidine and a pH of 6.9. In some embodiments, a formulation comprises histidine and a pH of 7.0. In some embodiments, a formulation comprises histidine and a pH of 7.1. In some embodiments, a formulation comprises histidine and a pH of 7.2.Salts

[0174] In some embodiments of the invention, a formulation further comprises a salt. Suitable salts include, for example, sodium chloride, potassium chloride, sodium sulfate,sodium acetate, and magnesium chloride. In some embodiments, the formulation comprises a halide. In some embodiments, the halide comprises an alkali metal halide.

[0175] In some embodiments, the salt is sodium chloride (NaCl). In some embodiments, the formulation comprises NaCl at a concentration ranging from 10 mM to 250 mM. In some embodiments, the salt is sodium chloride (NaCl). In some embodiments, the formulation comprises NaCl at a concentration ranging from 10 mM to 175 mM. In some embodiments, the formulation comprises NaCl at a concentration ranging from 25 mM to 150 mM. In some embodiments, the formulation comprises NaCl at a concentration ranging from 50 mM to 125 mM. In some embodiments, the formulation comprises NaCl at a concentration ranging from 50 mM to 100 mM. In some embodiments, the formulation comprises NaCl at a concentration ranging from 55 mM to 100 mM. In some embodiments, the formulation comprises NaCl at a concentration ranging from 75 mM to 125 mM. In some embodiments, the formulation comprises NaCl at a concentration ranging from 80 mM to 110 mM.

[0176] In some embodiments the formulation comprises 10 mM of sodium chloride. In some embodiments the formulation comprises 15 mM of sodium chloride. In some embodiments the formulation comprises 20 mM of sodium chloride. In some embodiments the formulation comprises 25 mM of sodium chloride. In some embodiments the formulation comprises 30 mM of sodium chloride. In some embodiments the formulation comprises 35 mM of sodium chloride. In some embodiments the formulation comprises 40 mM of sodium chloride. In some embodiments the formulation comprises 45 mM of sodium chloride. In some embodiments the formulation comprises 50 mM of sodium chloride. In some embodiments the formulation comprises 55 mM of sodium chloride. In some embodiments the formulation comprises 60 mM of sodium chloride. In some embodiments the formulation comprises 10 mM of sodium chloride. In some embodiments the formulation comprises 65 mM of sodium chloride. In some embodiments the formulation comprises 70 mM of sodium chloride. In some embodiments the formulation comprises 75 mM of sodium chloride. In some embodiments the formulation comprises 80 mM of sodium chloride. In some embodiments the formulation comprises 85 mM of sodium chloride. In some embodiments the formulation comprises 90 mM of sodium chloride. In some embodiments the formulation comprises 95 mM of sodium chloride. In some embodiments the formulation comprises 100 mM of sodium chloride. In some embodiments the formulation comprises 110 mM of sodium chloride. In some embodiments the formulation comprises 120 mM of sodiumchloride. In some embodiments the formulation comprises 125 mM of sodium chloride. In some embodiments the formulation comprises 130 mM of sodium chloride. In some embodiments the formulation comprises 140 mM of sodium chloride. In some embodiments the formulation comprises 150 mM of sodium chloride. In some embodiments the formulation comprises 160 mM of sodium chloride. In some embodiments the formulation comprises 170 mM of sodium chloride. In some embodiments the formulation comprises 175 mM of sodium chloride. In some embodiments the formulation comprises 180 mM of sodium chloride. In some embodiments the formulation comprises 190 mM of sodium chloride. In some embodiments the formulation comprises 200 mM of sodium chloride. In some embodiments the formulation comprises 225 mM of sodium chloride. In some embodiments the formulation comprises 250 mM of sodium chloride.

[0177] In some embodiments, the salt is magnesium chloride (MgCh). In some embodiments, the formulation comprises MgCh at a concentration ranging from 10 mM to 250 mM. In some embodiments, the salt is magnesium chloride (MgCh). In some embodiments, the formulation comprises MgCh at a concentration ranging from 10 mM to 175 mM. In some embodiments, the formulation comprises MgCh at a concentration ranging from 25 mM to 150 mM. In some embodiments, the formulation comprises MgCh at a concentration ranging from 50 mM to 125 mM. In some embodiments, the formulation comprises MgCh at a concentration ranging from 50 mM to 100 mM. In some embodiments, the formulation comprises MgCh at a concentration ranging from 75 mM to 125 mM. In some embodiments, the formulation comprises MgCh at a concentration ranging from 80 mM to 110 mM.

[0178] In some embodiments the formulation comprises 10 mM of magnesium chloride. In some embodiments the formulation comprises 15 mM of magnesium chloride. In some embodiments the formulation comprises 20 mM of magnesium chloride. In some embodiments the formulation comprises 25 mM of magnesium chloride. In some embodiments the formulation comprises 30 mM of magnesium chloride. In some embodiments the formulation comprises 35 mM of magnesium chloride. In some embodiments the formulation comprises 40 mM of magnesium chloride. In some embodiments the formulation comprises 45 mM of magnesium chloride. In some embodiments the formulation comprises 50 mM of magnesium chloride. In some embodiments the formulation comprises 55 mM of magnesium chloride. In some embodiments the formulation comprises 60 mM of magnesium chloride. In someembodiments the formulation comprises 10 mM of magnesium chloride. In some embodiments the formulation comprises 65 mM of magnesium chloride. In some embodiments the formulation comprises 70 mM of magnesium chloride. In some embodiments the formulation comprises 75 mM of magnesium chloride. In some embodiments the formulation comprises 80 mM of magnesium chloride. In some embodiments the formulation comprises 90 mM of magnesium chloride. In some embodiments the formulation comprises 100 mM of magnesium chloride. In some embodiments the formulation comprises 110 mM of magnesium chloride. In some embodiments the formulation comprises 120 mM of magnesium chloride. In some embodiments the formulation comprises 125 mM of magnesium chloride. In some embodiments the formulation comprises 130 mM of magnesium chloride. In some embodiments the formulation comprises 140 mM of magnesium chloride. In some embodiments the formulation comprises 150 mM of magnesium chloride. In some embodiments the formulation comprises 160 mM of magnesium chloride. In some embodiments the formulation comprises 170 mM of magnesium chloride. In some embodiments the formulation comprises 175 mM of magnesium chloride. In some embodiments the formulation comprises 180 mM of magnesium chloride. In some embodiments the formulation comprises 190 mM of magnesium chloride. In some embodiments the formulation comprises 200 mM of magnesium chloride. In some embodiments the formulation comprises 225 mM of magnesium chloride. In some embodiments the formulation comprises 250 mM of magnesium chloride.

[0179] In some embodiments, the salt is potassium chloride (KC1). In some embodiments, the formulation comprises KC1 at a concentration ranging from 10 mM to 250 mM. In some embodiments, the salt is potassium chloride (KC1). In some embodiments, the formulation comprises KC1 at a concentration ranging from 10 mM to 175 mM. In some embodiments, the formulation comprises KC1 at a concentration ranging from 25 mM to 150 mM. In some embodiments, the formulation comprises KC1 at a concentration ranging from 50 mM to 125 mM. In some embodiments, the formulation comprises KC1 at a concentration ranging from 50 mM to 100 mM. In some embodiments, the formulation comprises KC1 at a concentration ranging from 75 mM to 125 mM. In some embodiments, the formulation comprises KC1 at a concentration ranging from 80 mM to 110 mM.

[0180] In some embodiments the formulation comprises 10 mM of potassium chloride. In some embodiments the formulation comprises 15 mM of potassium chloride. Insome embodiments the formulation comprises 20 mM of potassium chloride. In some embodiments the formulation comprises 25 mM of potassium chloride. In some embodiments the formulation comprises 30 mM of potassium chloride. In some embodiments the formulation comprises 35 mM of potassium chloride. In some embodiments the formulation comprises 40 mM of potassium chloride. In some embodiments the formulation comprises 45 mM of potassium chloride. In some embodiments the formulation comprises 50 mM of potassium chloride. In some embodiments the formulation comprises 55 mM of potassium chloride. In some embodiments the formulation comprises 60 mM of potassium chloride. In some embodiments the formulation comprises 10 mM of potassium chloride. In some embodiments the formulation comprises 65 mM of potassium chloride. In some embodiments the formulation comprises 70 mM of potassium chloride. In some embodiments the formulation comprises 75 mM of potassium chloride. In some embodiments the formulation comprises 80 mM of potassium chloride. In some embodiments the formulation comprises 90 mM of potassium chloride. In some embodiments the formulation comprises 100 mM of potassium chloride. In some embodiments the formulation comprises 110 mM of potassium chloride. In some embodiments the formulation comprises 120 mM of potassium chloride. In some embodiments the formulation comprises 125 mM of potassium chloride. In some embodiments the formulation comprises 130 mM of potassium chloride. In some embodiments the formulation comprises 140 mM of potassium chloride. In some embodiments the formulation comprises 150 mM of potassium chloride. In some embodiments the formulation comprises 160 mM of potassium chloride. In some embodiments the formulation comprises 170 mM of potassium chloride. In some embodiments the formulation comprises 175 mM of potassium chloride. In some embodiments the formulation comprises 180 mM of potassium chloride. In some embodiments the formulation comprises 190 mM of potassium chloride. In some embodiments the formulation comprises 200 mM of potassium chloride. In some embodiments the formulation comprises 225 mM of potassium chloride. In some embodiments the formulation comprises 250 mM of potassium chloride.

[0181] In some embodiments, the salt is sodium sulfate. In some embodiments, the formulation comprises sodium sulfate at a concentration ranging from 10 mM to 250 mM. In some embodiments, the salt is sodium sulfate. In some embodiments, the formulation comprises sodium sulfate at a concentration ranging from 10 mM to 175 mM. In someembodiments, the formulation comprises sodium sulfate at a concentration ranging from 25 mM to 150 mM. In some embodiments, the formulation comprises sodium sulfate at a concentration ranging from 50 mM to 125 mM. In some embodiments, the formulation comprises sodium sulfate at a concentration ranging from 50 mM to 100 mM. In some embodiments, the formulation comprises sodium sulfate at a concentration ranging from 75 mM to 125 mM. In some embodiments, the formulation comprises sodium sulfate at a concentration ranging from 80 mM to 110 mM.

[0182] In some embodiments the formulation comprises 10 mM of sodium sulfate. In some embodiments the formulation comprises 15 mM of sodium sulfate. In some embodiments the formulation comprises 20 mM of sodium sulfate. In some embodiments the formulation comprises 25 mM of sodium sulfate. In some embodiments the formulation comprises 30 mM of sodium sulfate. In some embodiments the formulation comprises 35 mM of sodium sulfate. In some embodiments the formulation comprises 40 mM of sodium sulfate. In some embodiments the formulation comprises 45 mM of sodium sulfate. In some embodiments the formulation comprises 50 mM of sodium sulfate. In some embodiments the formulation comprises 55 mM of sodium sulfate. In some embodiments the formulation comprises 60 mM of sodium sulfate. In some embodiments the formulation comprises 10 mM of sodium sulfate. In some embodiments the formulation comprises 65 mM of sodium sulfate. In some embodiments the formulation comprises 70 mM of sodium sulfate. In some embodiments the formulation comprises 75 mM of sodium sulfate. In some embodiments the formulation comprises 80 mM of sodium sulfate. In some embodiments the formulation comprises 90 mM of sodium sulfate. In some embodiments the formulation comprises 100 mM of sodium sulfate. In some embodiments the formulation comprises 110 mM of sodium sulfate. In some embodiments the formulation comprises 120 mM of sodium sulfate. In some embodiments the formulation comprises 125 mM of sodium sulfate. In some embodiments the formulation comprises 130 mM of sodium sulfate. In some embodiments the formulation comprises 140 mM of sodium sulfate. In some embodiments the formulation comprises 150 mM of sodium sulfate. In some embodiments the formulation comprises 160 mM of sodium sulfate. In some embodiments the formulation comprises 170 mM of sodium sulfate. In some embodiments the formulation comprises 175 mM of sodium sulfate. In some embodiments the formulation comprises 180 mM of sodium sulfate. In some embodiments the formulation comprises 190 mM of sodium sulfate. In some embodiments the formulation comprises 200 mM of sodium sulfate. In some embodiments the formulationcomprises 225 mM of sodium sulfate. In some embodiments the formulation comprises 250 mM of sodium sulfate.

[0183] In some embodiments, the salt is sodium acetate. In some embodiments, the formulation comprises sodium acetate. In some embodiments, the formulation comprises sodium acetate at a concentration ranging from 5 mM to 100 mM. In some embodiments, the formulation comprises sodium acetate at a concentration ranging from 5 mM to 90 mM. In some embodiments, the formulation comprises sodium acetate at a concentration ranging from 15 mM to 80 mM. In some embodiments, the formulation comprises sodium acetate at a concentration ranging from 20 mM to 75 mM. In some embodiments, the formulation comprises sodium acetate at a concentration ranging from 25 mM to 50 mM. In some embodiments, the formulation comprises sodium acetate at a concentration ranging from 10 mM to 250 mM. In some embodiments, the salt is sodium acetate. In some embodiments, the formulation comprises sodium acetate at a concentration ranging from 10 mM to 175 mM. In some embodiments, the formulation comprises sodium acetate at a concentration ranging from 25 mM to 150 mM. In some embodiments, the formulation comprises sodium acetate at a concentration ranging from 50 mM to 125 mM. In some embodiments, the formulation comprises sodium acetate at a concentration ranging from 50 mM to 100 mM. In some embodiments, the formulation comprises sodium acetate at a concentration ranging from 75 mM to 125 mM. In some embodiments, the formulation comprises sodium acetate at a concentration ranging from 80 mM to 110 mM.

[0184] In some embodiments the formulation comprises 5 mM of sodium acetate. In some embodiments the formulation comprises 10 mM of sodium acetate. In some embodiments the formulation comprises 15 mM of sodium acetate. In some embodiments the formulation comprises 20 mM of sodium acetate. In some embodiments the formulation comprises 25 mM of sodium acetate. In some embodiments the formulation comprises 30 mM of sodium acetate. In some embodiments the formulation comprises 35 mM of sodium sulfate. In some embodiments the formulation comprises 40 mM of sodium acetate. In some embodiments the formulation comprises 45 mM of sodium acetate. In some embodiments the formulation comprises 50 mM of sodium acetate. In some embodiments the formulation comprises 55 mM of sodium acetate. In some embodiments the formulation comprises 60 mM of sodium acetate. In some embodiments the formulation comprises 65 mM of sodium acetate. In some embodiments the formulation comprises 70 mM of sodium acetate. In some embodiments the formulation comprises 75 mM of sodium acetate. In some embodimentsthe formulation comprises 80 mM of sodium acetate. In some embodiments the formulation comprises 85 mM of sodium acetate. In some embodiments the formulation comprises 90 mM of sodium acetate. In some embodiments the formulation comprises 95 mM of sodium acetate. In some embodiments the formulation comprises 100 mM of sodium acetate. In some embodiments the formulation comprises 110 mM of sodium acetate. In some embodiments the formulation comprises 120 mM of sodium acetate. In some embodiments the formulation comprises 125 mM of sodium acetate. In some embodiments the formulation comprises 130 mM of sodium acetate. In some embodiments the formulation comprises 140 mM of sodium acetate. In some embodiments the formulation comprises 150 mM of sodium acetate. In some embodiments the formulation comprises 160 mM of sodium acetate. In some embodiments the formulation comprises 170 mM of sodium acetate. In some embodiments the formulation comprises 175 mM of sodium acetate. In some embodiments the formulation comprises 180 mM of sodium acetate. In some embodiments the formulation comprises 190 mM of sodium acetate. In some embodiments the formulation comprises 200 mM of sodium acetate. In some embodiments the formulation comprises 225 mM of sodium acetate. In some embodiments the formulation comprises 250 mM of sodium acetate.Osmolyte

[0185] In some embodiments, a formulation comprises an osmolyte. In some embodiments, osmolytes provide stability to the folded, functional form of an antibody and alter the folding balance away from aggregation and / or degradation of the antibody. In some embodiments, an osmolyte is a tonicity agent. In some embodiments, an osmolyte is a sugar or polyol stabilizers.

[0186] In some embodiments, a formulation comprises a sugar. In some embodiments, a sugar is sucrose. In some embodiments, a sugar is trehalose. In some embodiments, a sugar is maltose. In some embodiments, a sugar is a disaccharide.

[0187] In some embodiments, a formulation comprises 0.5-20% (w / v) sugar. In some embodiments, the concentration of sugar is expressed in mg / ml. For example, 35 mg / ml of sugar is equivalent to 3.5 % (w / v).

[0188] In some embodiments, a formulation comprises 1-15% (w / v) sugar. In some embodiments, a formulation comprises 3-12% (w / v) sugar. In some embodiments, a formulation comprises 3.5-7% (w / v) sugar. In some embodiments, a formulation comprises 4-8% (w / v) sugar. In some embodiments, a formulation comprises 5-7% (w / v) sugar. Insome embodiments, a formulation comprises 5-8% (w / v) sugar. In some embodiments, a formulation comprises 1% (w / v) sugar. In some embodiments, a formulation comprises 2% (w / v) sugar. In some embodiments, a formulation comprises 3% (w / v) sugar. In some embodiments, a formulation comprises 3.5% (w / v) sugar. In some embodiments, a formulation comprises 4% (w / v) sugar. In some embodiments, a formulation comprises 5% (w / v) sugar. In some embodiments, a formulation comprises 6% (w / v) sugar. In some embodiments, a formulation comprises 7% (w / v) sugar. In some embodiments, a formulation comprises 8% (w / v) sugar. In some embodiments, a formulation comprises 9% (w / v) sugar. In some embodiments, a formulation comprises 10% (w / v) sugar. In some embodiments, a formulation comprises 11% (w / v) sugar. In some embodiments, a formulation comprises 12% (w / v) sugar. In some embodiments, a formulation comprises 13% (w / v) sugar. In some embodiments, a formulation comprises 14% (w / v) sugar. In some embodiments, a formulation comprises 15% (w / v) sugar. In some embodiments, a formulation comprises 16% (w / v) sugar. In some embodiments, a formulation comprises 17% (w / v) sugar. In some embodiments, a formulation comprises 18% (w / v) sugar. In some embodiments, a formulation comprises 19% (w / v) sugar. In some embodiments, a formulation comprises 20% (w / v) sugar.

[0189] In some embodiments, a formulation comprises 1-15% (w / v) sucrose. In some embodiments, a formulation comprises 3-12% (w / v) sucrose. In some embodiments, a formulation comprises 3.5-7% (w / v) sucrose. In some embodiments, a formulation comprises 4-8% (w / v) sucrose. In some embodiments, a formulation comprises 5-7% (w / v) sucrose. In some embodiments, a formulation comprises 5-8% (w / v) sucrose. In some embodiments, a formulation comprises 1% (w / v) sucrose. In some embodiments, a formulation comprises 2% (w / v) sucrose. In some embodiments, a formulation comprises 3% (w / v) sucrose. In some embodiments, a formulation comprises 3.5% (w / v) sucrose. In some embodiments, a formulation comprises 4% (w / v) sucrose. In some embodiments, a formulation comprises 5% (w / v) sucrose. In some embodiments, a formulation comprises 6% (w / v) sucrose. In some embodiments, a formulation comprises 7% (w / v) sucrose. In some embodiments, a formulation comprises 8% (w / v) sucrose. In some embodiments, a formulation comprises 9% (w / v) sucrose. In some embodiments, a formulation comprises 10% (w / v) sucrose. In some embodiments, a formulation comprises 11% (w / v) sucrose. In some embodiments, a formulation comprises 12% (w / v) sucrose. In some embodiments, a formulation comprises 13% (w / v) sucrose. In some embodiments, a formulation comprises14% (w / v) sucrose. In some embodiments, a formulation comprises 15% (w / v) sucrose. In some embodiments, a formulation comprises 16% (w / v) sucrose. In some embodiments, a formulation comprises 17% (w / v) sucrose. In some embodiments, a formulation comprises 18% (w / v) sucrose. In some embodiments, a formulation comprises 19% (w / v) sucrose. In some embodiments, a formulation comprises 20% (w / v) sucrose.

[0190] In some embodiments, a formulation comprises 1-15% (w / v) trehalose. In some embodiments, a formulation comprises 3-12% (w / v) trehalose. In some embodiments, a formulation comprises 4-8% (w / v) trehalose. In some embodiments, a formulation comprises 5-7% (w / v) trehalose. In some embodiments, a formulation comprises 1% (w / v) trehalose. In some embodiments, a formulation comprises 2% (w / v) trehalose. In some embodiments, a formulation comprises 3% (w / v) trehalose. In some embodiments, a formulation comprises 4% (w / v) trehalose. In some embodiments, a formulation comprises 5% (w / v) trehalose. In some embodiments, a formulation comprises 6% (w / v) trehalose. In some embodiments, a formulation comprises 7% (w / v) trehalose. In some embodiments, a formulation comprises 8% (w / v) trehalose. In some embodiments, a formulation comprises 9% (w / v) trehalose. In some embodiments, a formulation comprises 10% (w / v) trehalose. In some embodiments, a formulation comprises 11% (w / v) trehalose. In some embodiments, a formulation comprises 12% (w / v) trehalose. In some embodiments, a formulation comprises 13% (w / v) trehalose. In some embodiments, a formulation comprises 14% (w / v) trehalose. In some embodiments, a formulation comprises 15% (w / v) trehalose. In some embodiments, a formulation comprises 16% (w / v) trehalose. In some embodiments, a formulation comprises 17% (w / v) trehalose. In some embodiments, a formulation comprises 18% (w / v) trehalose. In some embodiments, a formulation comprises 19% (w / v) trehalose. In some embodiments, a formulation comprises 20% (w / v) trehalose.

[0191] In some embodiments, a formulation comprises 1-15% (w / v) maltose. In some embodiments, a formulation comprises 3-12% (w / v) maltose. In some embodiments, a formulation comprises 4-8% (w / v) maltose. In some embodiments, a formulation comprises 5-7% (w / v) maltose. In some embodiments, a formulation comprises 1% (w / v) maltose. In some embodiments, a formulation comprises 2% (w / v) maltose. In some embodiments, a formulation comprises 3% (w / v) maltose. In some embodiments, a formulation comprises 4% (w / v) maltose. In some embodiments, a formulation comprises 5% (w / v) maltose. In some embodiments, a formulation comprises 6% (w / v) maltose. In some embodiments, a formulation comprises 7% (w / v) maltose. In some embodiments, a formulation comprises 8%(w / v) maltose. In some embodiments, a formulation comprises 9% (w / v) maltose. In some embodiments, a formulation comprises 10% (w / v) maltose. In some embodiments, a formulation comprises 11% (w / v) maltose. In some embodiments, a formulation comprises 12% (w / v) maltose. In some embodiments, a formulation comprises 13% (w / v) maltose. In some embodiments, a formulation comprises 14% (w / v) maltose. In some embodiments, a formulation comprises 15% (w / v) maltose. In some embodiments, a formulation comprises 16% (w / v) maltose. In some embodiments, a formulation comprises 17% (w / v) maltose. In some embodiments, a formulation comprises 18% (w / v) maltose. In some embodiments, a formulation comprises 19% (w / v) maltose. In some embodiments, a formulation comprises 20% (w / v) maltose.

[0192] In some embodiments, a formulation comprises 1-15% (w / v) polyol. In some embodiments, a formulation comprises 3-12% (w / v) polyol. In some embodiments, a formulation comprises 4-8% (w / v) polyol. In some embodiments, a formulation comprises 5- 7% (w / v) polyol. In some embodiments, a formulation comprises 1% (w / v) polyol. In some embodiments, a formulation comprises 2% (w / v) polyol. In some embodiments, a formulation comprises 3% (w / v) polyol. In some embodiments, a formulation comprises 4% (w / v) polyol. In some embodiments, a formulation comprises 5% (w / v) polyol. In some embodiments, a formulation comprises 6% (w / v) polyol. In some embodiments, a formulation comprises 7% (w / v) polyol. In some embodiments, a formulation comprises 8% (w / v) polyol. In some embodiments, a formulation comprises 9% (w / v) polyol. In some embodiments, a formulation comprises 10% (w / v) polyol. In some embodiments, a formulation comprises 11% (w / v) polyol. In some embodiments, a formulation comprises 12% (w / v) polyol. In some embodiments, a formulation comprises 13% (w / v) polyol. In some embodiments, a formulation comprises 14% (w / v) polyol. In some embodiments, a formulation comprises 15% (w / v) polyol. In some embodiments, a formulation comprises 16% (w / v) polyol. In some embodiments, a formulation comprises 17% (w / v) polyol. In some embodiments, a formulation comprises 18% (w / v) polyol. In some embodiments, a formulation comprises 19% (w / v) polyol. In some embodiments, a formulation comprises 20% (w / v) polyol. In some embodiments, a polyol is sorbitol. In some embodiments, a polyol is mannitol. In some embodiments, a polyol is glycerol.Surfactants

[0193] In some embodiments, a formulation comprises a surfactant. In some embodiments, a surfactant is a polysorbate-20. In some embodiments, a surfactant is a polysorbate-80. In some embodiments, a surfactant is a poloxamer 188.

[0194] In some embodiments, a formulation comprises 0.005-2% (w / v) surfactant. In some embodiments, the concentration of surfactant is expressed in mg / ml. One of a person skilled in the art would be able to convert mg / ml to w / v %.

[0195] In some embodiments, a formulation comprises 0.01-1.0% (w / v) surfactant.In some embodiments, a formulation comprises 0.02-0.5% (w / v) surfactant. In some embodiments, a formulation comprises 0.02-0.1% (w / v) surfactant. In some embodiments, a formulation comprises 0.01-0.1% (w / v) surfactant. In some embodiments, a formulation comprises 0.01-0.05% (w / v) surfactant. In some embodiments, a formulation comprises 0.02- 0.05% (w / v) surfactant. In some embodiments, a formulation comprises 0.005% (w / v) surfactant. In some embodiments, a formulation comprises 0.01% (w / v) surfactant. In some embodiments, a formulation comprises 0.015% (w / v) surfactant. In some embodiments, a formulation comprises 0.02% (w / v) surfactant. In some embodiments, a formulation comprises 0.03% (w / v) surfactant. In some embodiments, a formulation comprises 0.04% (w / v) surfactant. In some embodiments, a formulation comprises 0.05% (w / v) surfactant. In some embodiments, a formulation comprises 0.06% (w / v) surfactant. In some embodiments, a formulation comprises 0.07% (w / v) surfactant. In some embodiments, a formulation comprises 0.08% (w / v) surfactant. In some embodiments, a formulation comprises 0.09% (w / v) surfactant. In some embodiments, a formulation comprises 0.10% (w / v) surfactant. In some embodiments, a formulation comprises 0.11% (w / v) surfactant. In some embodiments, a formulation comprises 0.12% (w / v) surfactant. In some embodiments, a formulation comprises 0.13% (w / v) surfactant. In some embodiments, a formulation comprises 0.14% (w / v) surfactant. In some embodiments, a formulation comprises 0.15% (w / v) surfactant. In some embodiments, a formulation comprises 0.16% (w / v) surfactant. In some embodiments, a formulation comprises 0.17% (w / v) surfactant. In some embodiments, a formulation comprises 0.18% (w / v) surfactant. In some embodiments, a formulation comprises 0.19% (w / v) surfactant. In some embodiments, a formulation comprises 0.2% (w / v) surfactant. In some embodiments, a formulation comprises 0.25% (w / v) surfactant. In some embodiments, a formulation comprises 0.3% (w / v) surfactant. In some embodiments, a formulation comprises 0.4% (w / v) surfactant. In some embodiments, a formulation comprises 0.5% (w / v) surfactant. In some embodiments, a formulation comprises 0.6% (w / v) surfactant. In someembodiments, a formulation comprises 0.7% (w / v) surfactant. In some embodiments, a formulation comprises 0.8% (w / v) surfactant. In some embodiments, a formulation comprises 0.9% (w / v) surfactant. In some embodiments, a formulation comprises 1.0% (w / v) surfactant. In some embodiments, a formulation comprises 1.2% (w / v) surfactant. In some embodiments, a formulation comprises 1.5% (w / v) surfactant. In some embodiments, a formulation comprises 1.8% (w / v) surfactant. In some embodiments, a formulation comprises 2.0% (w / v) surfactant.

[0196] In some embodiments, a formulation comprises 0.01-1.0% (w / v) polysorbate- 20. In some embodiments, a formulation comprises 0.02-0.5% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.02-0.1% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.01-0.1% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.01-0.05% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.02-0.05% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.005% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.01% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.015% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.02% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.03% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.04% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.05% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.06% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.07% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.08% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.09% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.10% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.11% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.12% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.13% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.14% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.15% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.16% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.17% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.18% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.19% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.2% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.25% (w / v) polysorbate-20. In some embodiments, a formulationcomprises 0.3% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.4% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.5% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.6% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.7% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.8% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.9% (w / v) polysorbate-20. In some embodiments, a formulation comprises 1.0% (w / v) polysorbate-20. In some embodiments, a formulation comprises 1.2% (w / v) polysorbate-20. In some embodiments, a formulation comprises 1.5% (w / v) polysorbate-20. In some embodiments, a formulation comprises 1.8% (w / v) polysorbate-20. In some embodiments, a formulation comprises 2.0% (w / v) polysorbate-20.

[0197] In some embodiments, a formulation comprises 0.01-1.0% (w / v) polysorbate- 80. In some embodiments, a formulation comprises 0.02-0.5% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.02-0.1% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.01-0.1% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.01-0.05% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.02-0.05% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.005% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.01% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.015% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.02% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.03% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.04% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.05% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.06% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.07% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.08% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.09% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.10% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.11% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.12% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.13% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.14% (w / v) polysorbate-20. In some embodiments, a formulation comprises 0.15% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.16% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.17% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.18% (w / v) polysorbate-80.In some embodiments, a formulation comprises 0.19% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.2% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.25% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.3% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.4% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.5% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.6% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.7% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.8% (w / v) polysorbate-80. In some embodiments, a formulation comprises 0.9% (w / v) polysorbate-80. In some embodiments, a formulation comprises 1.0% (w / v) polysorbate-80. In some embodiments, a formulation comprises 1.2% (w / v) polysorbate-80. In some embodiments, a formulation comprises 1.5% (w / v) polysorbate-80. In some embodiments, a formulation comprises 1.8% (w / v) polysorbate-80. In some embodiments, a formulation comprises 2.0% (w / v) polysorbate-80.

[0198] In some embodiments, a formulation comprises 0.01-1.0% (w / v) poloxamer- 188. In some embodiments, a formulation comprises 0.02-0.5% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.02-0.1% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.01-0.1% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.01-0.05% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.02-0.05% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.005% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.01% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.015% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.02% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.03% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.04% (w / v) poloxamer- 188. In some embodiments, a formulation comprises 0.05% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.06% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.07% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.08% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.09% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.10% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.11% (w / v) poloxamer- 188. In some embodiments, a formulation comprises 0.12% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.13% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.14% (w / v) poloxamer-188. In some embodiments, a formulationcomprises 0.15% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.16% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.17% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.18% (w / v) poloxamer- 188. In some embodiments, a formulation comprises 0.19% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.2% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.25% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.3% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.4% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.5% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.6% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.7% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.8% (w / v) poloxamer-188. In some embodiments, a formulation comprises 0.9% (w / v) poloxamer-188. In some embodiments, a formulation comprises 1.0% (w / v) poloxamer-188. In some embodiments, a formulation comprises 1.2% (w / v) poloxamer-188. In some embodiments, a formulation comprises 1.5% (w / v) poloxamer-188. In some embodiments, a formulation comprises 1.8% (w / v) poloxamer-188. In some embodiments, a formulation comprises 2.0% (w / v) poloxamer-188.Stability and Properties of Antibody Formulation

[0199] In some embodiments of the invention, formulations were optimized in order to increase stability. The stability of an antibody formulation can be quantified in several ways. In some embodiments, stability of an antibody formulation is characterized by the amount of HMW species of an anti-ILlRl antibody or the rate of increase of the amount of HMW species of an anti-ILlRl antibody. In certain embodiments, the rate of increase of HMW species is determined at 2, 4, 6 or 8 weeks in storage and at approximately 5°C, 25°C or 40°C. In some embodiments, stability of an antibody formulation is characterized by charge distribution, e.g., a change in the amount of the charge variant peaks of the antibody. In some embodiments, stability of an antibody formulation is characterized by dynamic light scattering, analytical ultracentrifugation (AUC), field flow fractionation (FFF), isoelectric focusing and ion exchange chromatography (IEX). In some embodiments, stability of an antibody formulation is characterized by partial dissociation as measured by sodium-dodecyl sulfate capillary electrophoresis (CE-SDS) and / or sodium-dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).

[0200] The stability of an anti-ILlRl antibody, and the capability of the formulation to maintain stability of the anti-ILlRl antibody, may be assessed over extended periods of time (e.g., weeks or months). In the context of a formulation, a stable formulation is one in which the antibody therein essentially retains its physical and / or chemical integrity and biological activity upon storage and during processes such as freeze / thaw, mechanical mixing and lyophilization. Antibody stability can be measured by formation of high molecular weight (HMW) aggregates, shift of charge profiles, and change in particle size.

[0201] Stability of an antibody may be assessed relative to the biological activity or physiochemical integrity of the antibody over extended periods of time. For example, stability at a given time point may be compared against stability at an earlier time point (e.g., upon formulation day 0), against unformulated antibody, or against a differently formulated antibody and the results of this comparison expressed as a percentage. Preferably, the antibody formulations of the present invention maintain at least 100%, at least 99%, at least 98%, at least 97% at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55% or at least 50% of the antibody’s biological activity, physiochemical integrity, and / or particle size over an extended period of time (e.g., as measured over at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, or 36 months, at room temperature or under accelerated storage conditions). In some embodiments, the percent values indicating protein levels as disclosed herein or throughout the specification, are expressed relative to the total protein in the formulation. In some embodiments, the relative values of any particular species of the product, as disclosed herein or throughout the specification, such as the monomeric IgG form or species, or the high molecular weight (HMW) form, or the aggregated forms, are expressed in relation to the total value of the total product.High-Molecular Weight (HMW) Species

[0202] In some embodiments, less than 55%, 50%, 40%, 30%, 20%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1.5%, 1%, or 0.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks, at least 6 weeks, at least 2 months, at least 3 months, at least 4 months, at least 6 months, at least 8 months, at least 10 months, or at least 12 months. In some embodiments, less than 10% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, less than 8% of an anti-ILlRl antibody exists as HMW species in aformulation upon storage at 5°C for at least 4 weeks. In some embodiments, less than 6% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, less than 5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, less than 4% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, less than 3% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, less than 2.6 % of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, less than 2.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, less than 2.4% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, less than 2.3% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, less than 2.2% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, less than 2.1% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, less than 2% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, less than 1.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, less than 1% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, less than 0.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, less than 0.4% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks In some embodiments, less than 0.3% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, less than 0.2% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, less than 0.1% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, the formulation is substantially free of HMW species upon storage at 5°C for at least 4 weeks.

[0203] In some embodiments, less than 10% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 8% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 6% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 4% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 3% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 2.9 % of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 2.8 % of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 2.7 % of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 2.6 % of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 2.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 2.4% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 2.3% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 2.2% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 2.1% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 2% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 1% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 0.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 0.4% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 0.3% of an anti-ILlRl antibody exists as HMW species in aformulation upon storage at 5°C for at least 2 months. In some embodiments, less than 0.2% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, less than 0.1% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for at least 2 months. In some embodiments, the formulation is substantially free of HMW species upon storage at 5°C for at least 2 months.

[0204] In some embodiments, 5% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for 3 months. In some embodiments, 4% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for 3 months. In some embodiments, 4% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for 3 months. In some embodiments, 3% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for 3 months. In some embodiments, 2% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for 3 months. In some embodiments, 1.5% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for 3 months. In some embodiments, 1% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for 3 months.

[0205] In some embodiments, 5% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for 6 months. In some embodiments, 4% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for 6 months. In some embodiments, 3% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for 6 months. In some embodiments, less than 2% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for 6 months. In some embodiments, 1% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 5°C for 6 months.

[0206] In some embodiments, less than 10%, 8%, 5%, 4%, 3%, 2.5%, 2%, 1%, or 0.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks, at least 6 weeks, at least 2 months, at least 3 months, at least 4 months, at least 6 months, at least 8 months, at least 10 months, or at least 12 months. In some embodiments, less than 10% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 8% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for atleast 4 weeks. In some embodiments, less than 6% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 4% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 3.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 3.4% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 3.3% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 3.2% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 3.1% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 3% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 2.9% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 2.8% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 2.7% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 2.6% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 2.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 2.4% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 2.3% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 2.2% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 2.1% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 2% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 1.8% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C forat least 4 weeks. In some embodiments, less than 1.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 1% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 0.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 0.4% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 0.3% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 0.2% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, less than 0.1% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, the formulation is substantially free of HMW species upon storage at 25°C for at least 4 weeks.

[0207] In some embodiments, less than 10% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 8% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 6% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 4.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 4.4% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 4.3% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 4.2% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 4.1% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 4% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 3.9% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than3.8% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 3.7% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 3.6% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 3.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 3.4% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 3.3% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 3.2% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 3.1% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 3% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 2.9% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 2.8% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 2.7% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 2.6% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 2.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 2.4% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 2.3% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 2.2% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 2.1% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 2% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 1% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In someembodiments, less than 0.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 0.4% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 0.3% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 0.2% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, less than 0.1% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for at least 2 months. In some embodiments, the formulation is substantially free of HMW species upon storage at 25°C for at least 2 months.

[0208] In some embodiments, 5% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for 3 months. In some embodiments, 4% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for 3 months. In some embodiments, 3% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for 3 months. In some embodiments, 2.5% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for 3 months. In some embodiments, 2% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for 3 months. In some embodiments, 1% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for 3 months.

[0209] In some embodiments, 5% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for 6 months. In some embodiments, 4% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for 6 months. In some embodiments, less than 3% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for 6 months. In some embodiments, 2.5% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for 6 months. In some embodiments, 2% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for 6 months. In some embodiments, 1% or less of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 25°C for 6 months.

[0210] In some embodiments, less than 10%, 8%, 5%, 4%, 3%, 2%, 1%, or 0.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for atleast 4 weeks, at least 6 weeks, at least 2 months, at least 3 months, at least 4 months, at least 6 months, at least 8 months, at least 10 months, or at least 12 months. In some embodiments, less than 50% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 40% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 39% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 38% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 37% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 36% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 35% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 30% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 25% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 20% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 15% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 14% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 13% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 12% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 11% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 10% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 9% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 8% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 8% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for atleast 4 weeks. In some embodiments, less than 7% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 6% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 4% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 3% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 2% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 1.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 1% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 0.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 0.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 0.3% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 0.2% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, less than 0.1% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 weeks.

[0211] In some embodiments, less than 60% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 58% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 57% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 56% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 55% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 50% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 45% of an anti-ILlRl antibody exists asHMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 40% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 35% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 30% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 4 2 months. In some embodiments, less than 25% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 24% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 23% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 22% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 21% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 20% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 15% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 14% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 13% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 12% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 11% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 10% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 9% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 8% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 7% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 6% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 5%of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 4% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 3% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 2% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months. In some embodiments, less than 1% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for at least 2 months.

[0212] In some embodiments, less than 5% of an anti-ILlRl antibody exists asHMW species in a formulation upon storage at 40°C for 3 months. In some embodiments, less than 4.5% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for 3 months.

[0213] In some embodiments, less than 15% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for 6 months. In some embodiments, less than 11% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for 6 months. In some embodiments, less than 10% of an anti-ILlRl antibody exists as HMW species in a formulation upon storage at 40°C for 6 months. In some embodiments, the percentage of HMW species that exists in the formulation is evaluated by size exclusion chromatography (SEC). In some embodiments, the percentage of higher molecular weight species in the formulation (AHMW%) is evaluated at 60% relative humidity. In some embodiments, the percentage of higher molecular weight species in the formulation (AHMW%) is evaluated at 75% relative humidity.

[0214] In some embodiments, the amount of HMW species in a formulation increases less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.2% or 0.1% upon storage at 5°C for more than 2 weeks, more than 4 weeks, more than 6 weeks, more than 2 months, more than 3 months, more than 4 months, more than 6 months, more than 8 months, more than 10 months, or more than 12 months. In some embodiments, upon storage at 5°C for 4 weeks, the amount of HMW species in the formulation does not substantially increase. In some embodiments, upon storage at 5°C for 4 weeks, the amount of HMW species in the formulation increases less than 10%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of HMW species in the formulation increases 8% or less. In some embodiments, upon storage at 5°C for 4 weeks, the amount of HMW species in the formulation increasesless than 5%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of HMW species in the formulation increases less than 4%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of HMW species in the formulation increases less than 3%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of HMW species in the formulation increases less than 2%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of HMW species in the formulation increases less than 1.5%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of HMW species in the formulation increases less than 1.0%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of HMW species in the formulation increases less than 0.8%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of HMW species in the formulation increases less than 0.6%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of HMW species in the formulation increases less than 0.5%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of HMW species in the formulation increases less than 0.4%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of HMW species in the formulation increases less than 0.3%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of HMW species in the formulation increases less than 0.2%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of HMW species in the formulation increases less than 0.1%.

[0215] In some embodiments, upon storage at 5°C for 2 months, the amount of HMW species in the formulation does not substantially increase. In some embodiments, upon storage at 5°C for 2 months, the amount of HMW species in the formulation increases less than 5%. In some embodiments, upon storage at 5°C for 2 months, the amount of HMW species in the formulation increases less than 4%. In some embodiments, upon storage at 5°C for 2 months, the amount of HMW species in the formulation increases less than 3%. In some embodiments, upon storage at 5°C for 2 months, the amount of HMW species in the formulation increases less than 2%. In some embodiments, upon storage at 5°C for 2 months, the amount of HMW species in the formulation increases less than 1.5%. In some embodiments, upon storage at 5°C for 2 months, the amount of HMW species in the formulation increases less than 1.0%. In some embodiments, upon storage at 5°C for 2 months, the amount of HMW species in the formulation increases less than 0.8%. In some embodiments, upon storage at 5°C for 2 months, the amount of HMW species in the formulation increases less than 0.6%. In some embodiments, upon storage at 5°C for 2 months, the amount of HMW species in the formulation increases less than 0.5%. In someembodiments, upon storage at 5°C for 2 months, the amount of HMW species in the formulation increases less than 0.4%. In some embodiments, upon storage at 5°C for 2 months, the amount of HMW species in the formulation increases less than 0.3%. In some embodiments, upon storage at 5°C for 2 months, the amount of HMW species in the formulation increases less than 0.2%. In some embodiments, upon storage at 5°C for 2 months, the amount of HMW species in the formulation increases less than 0.1%.

[0216] In some embodiments, upon storage at 5°C for 3 months, the amount of HMW species in the formulation increases less than 20%. In some embodiments, upon storage at 5°C for 3 months, the amount of HMW species in the formulation increases less than 16%. In some embodiments, upon storage at 5°C for 3 months, the amount of HMW species in the formulation increases 15% or less. In some embodiments, upon storage at 5°C for 3 months, the amount of HMW species in the formulation increases less than 10%.

[0217] In some embodiments, upon storage at 5°C for 6 months, the amount of HMW species in the formulation increases less than 30%. In some embodiments, upon storage at 5°C for 6 months, the amount of HMW species in the formulation increases less than 25%. In some embodiments, upon storage at 5°C for 6 months, the amount of HMW species in the formulation increases 23% or less.

[0218] In some embodiments, the amount of HMW species in a formulation increases less than 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.2% or 0.1% upon storage at 25°C for more than 2 weeks, more than 4 weeks, more than 6 weeks, more than 2 months, more than 3 months, more than 4 months, more than 6 months, more than 8 months, more than 10 months, or more than 12 months. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation does not substantially increase. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 35%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 34%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 33%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 32%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 31%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases 30% or less. In someembodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases 25% or less. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 20%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 15%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 10%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 5%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 4%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 3%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 2%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 1.5%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 1.0%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 0.9%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 0.8%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 0.7%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 0.6%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 0.5%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 0.4%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 0.3%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 0.2%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of HMW species in the formulation increases less than 0.1%.

[0219] In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation does not substantially increase. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 5%. In some embodiments, upon storage at 25°C for 2 months, the amount ofHMW species in the formulation increases less than 4%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 3%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 2%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 1.9%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 1.8%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 1.7%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 1.6%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 1.5%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 1.4%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 1.3%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 1.2%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 1.1%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 1.0%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 0.9%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 0.8%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 0.7%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 0.6%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 0.5%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 0.4%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 0.3%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 0.2%. In some embodiments, upon storage at 25°C for 2 months, the amount of HMW species in the formulation increases less than 0.1%.

[0220] In some embodiments, upon storage at 25°C for 3 months, the amount of HMW species in the formulation increases less than 60%. In some embodiments, upon storage at 25°C for 3 months, the amount of HMW species in the formulation increases less than 55%. In some embodiments, upon storage at 25°C for 3 months, the amount of HMW species in the formulation increases less than 54%. In some embodiments, upon storage at 25°C for 3 months, the amount of HMW species in the formulation increases 53% or less. In some embodiments, upon storage at 25°C for 3 months, the amount of HMW species in the formulation increases less than 50%.

[0221] In some embodiments, upon storage at 25°C for 6 months, the amount of HMW species in the formulation increases less than 80%. In some embodiments, upon storage at 25°C for 6 months, the amount of HMW species in the formulation increases less than 79%. In some embodiments, upon storage at 25°C for 6 months, the amount of HMW species in the formulation increases less than 78%. In some embodiments, upon storage at 25°C for 6 months, the amount of HMW species in the formulation increases less than 77%. In some embodiments, upon storage at 25°C for 6 months, the amount of HMW species in the formulation increases less than 76%. In some embodiments, upon storage at 25°C for 6 months, the amount of HMW species in the formulation increases less than 75%.

[0222] In some embodiments, the amount of HMW species in a formulation increases less than 735%, 255%, 200%, 100%, 75%, 55%, 50%, 45%, 40%, 38%, 35% 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1%, or 0.5% upon storage at 40°C for more than 2 weeks, more than 4 weeks, more than 6 weeks, more than 2 months, more than 3 months, more than 4 months, more than 6 months, more than 8 months, more than 10 months, or more than 12 months. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 255%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 250%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 100%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 50%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 45%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 40%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 39%. In some embodiments, upon storage at 40°C for 4weeks, the amount of HMW species in the formulation increases less than 38%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 37%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 36%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 35%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 30%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 25%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 20%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 15%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 14%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 13%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 12%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 11%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 10%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 9%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 8%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 7%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 6%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 5%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 4.8%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 4.5%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 4%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 3%. In some embodiments, upon storage at 40°C for 4 weeks,the amount of HMW species in the formulation increases less than 2.5%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 2%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 1.5%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 1.0%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 0.8%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 0.6%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of HMW species in the formulation increases less than 0.5%.

[0223] In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 60%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 59%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 58%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 57%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 56%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 55%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 54%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 53%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 52%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 51%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 50%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 45%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 40%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 35%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 30%. In some embodiments, upon storage at 40°C for 2months, the amount of HMW species in the formulation increases less than 25%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 24%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 23%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 22%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 21%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 20%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 15%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 10%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 9%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 8%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 7%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 6%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 5%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 4%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 3%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 2%. In some embodiments, upon storage at 40°C for 2 months, the amount of HMW species in the formulation increases less than 1.0%.

[0224] In some embodiments, upon storage at 40°C for 3 months, the amount of HMW species in the formulation increases less than 735%. In some embodiments, upon storage at 40°C for 3 months, the amount of HMW species in the formulation increases 730% or less. In some embodiments, the percent increase in higher molecular weight species in the formulation (AHMW%) is evaluated by size exclusion chromatography (SEC). In some embodiments, the percentage of higher molecular weight species in the formulation (AHMW%) is evaluated at 60% relative humidity. In some embodiments, the percentage ofhigher molecular weight species in the formulation (AHMW%) is evaluated at 75% relative humidity.Monomer

[0225] In some embodiments, at least 80%, 85%, 90%, 95%, or 98% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 5°C for at least 4 weeks, at least 6 weeks, at least 2 months, at least 3 months, at least 4 months, at least 6 months, at least 8 months, at least 10 months, or at least 12 months. In some embodiments, at least 90% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, at least 91% of an anti-ILlRl antibody exists as monomer in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, at least 92% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, at least 93% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, at least 94% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, at least 95% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, at least 96% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, at least 97% of an anti- IL1R1 antibody exists as monomers in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, at least 98% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 5°C for at least 4 weeks. In some embodiments, at least 99% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 5°C for at least 4 weeks.

[0226] In some embodiments, at least 90% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 5°C for at least 2 months. In some embodiments, at least 91% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 5°C for at least 2 months. In some embodiments, at least 92% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 5°C for at least 2 months. In some embodiments, at least 93% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 5°C for at least 2 months. In some embodiments, at least 94% of an anti- IL1R1 antibody exists as monomers in a formulation upon storage at 5°C for at least 2 months. In some embodiments, at least 95% of an anti-ILlRl antibody exists as monomersin a formulation upon storage at 5°C for at least 2 months. In some embodiments, at least 96% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 5°C for at least 2 months. In some embodiments, at least 97% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 5°C for at least 2 months. In some embodiments, at least 98% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 5°C for at least 2 months. In some embodiments, at least 99% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 5°C for at least 2 months.

[0227] In some embodiments, at least 80%, 85%, 90%, 95%, or 98% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 25°C for at least 4 weeks, at least 6 weeks, at least 2 months, at least 3 months, at least 4 months, at least 6 months, at least 8 months, at least 10 months, or at least 12 months. In some embodiments, at least 90% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, at least 91% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, at least 92% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, at least 93% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, at least 94% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, at least 95% of an anti- IL1R1 antibody exists as monomers in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, at least 96% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, at least 97% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, at least 98% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 25°C for at least 4 weeks. In some embodiments, at least 99% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 25°C for at least 4 weeks.

[0228] In some embodiments, at least 90% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 25°C for at least 2 months. In some embodiments, at least 91% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 25°C for at least 2 months. In some embodiments, at least 92% of an anti- IL1R1 antibody exists as monomers in a formulation upon storage at 25°C for at least 2 months. In some embodiments, at least 93% of an anti-ILlRl antibody exists as monomersin a formulation upon storage at 25°C for at least 2 months. In some embodiments, at least 94% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 25°C for at least 2 months. In some embodiments, at least 95% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 25°C for at least 2 months. In some embodiments, at least 96% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 25°C for at least 2 months. In some embodiments, at least 97% of an anti- IL1R1 antibody exists as monomers in a formulation upon storage at2 5°C for at least 2 months. In some embodiments, at least 98% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 25°C for at least 2 months. In some embodiments, at least 99% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 25°C for at least 2 months.

[0229] In some embodiments, at least 50%, 55%, 60% 80%, 85%, 90%, 95%, or 98% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks, at least 6 weeks, at least 2 months, at least 3 months, at least 4 months, at least 6 months, at least 8 months, at least 10 months, or at least 12 months. In some embodiments, at least 55% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 56% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 57% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 58% of an anti- IL1R1 antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 59% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 60% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 61% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 62% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 63% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 64% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 65% of an anti- IL1R1 antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 70% of an anti-ILlRl antibody exists as monomers ina formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 80% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 85% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 86% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 87% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 88% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 89% of an anti- IL1R1 antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 90% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 91% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 92% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 93% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 94% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 95% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 96% of an anti- IL1R1 antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 97% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 98% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, at least 99% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 4 weeks. In some embodiments, a formulation comprising an anti-ILlRl antibody does not gel upon storage at 40°C for at least 4 weeks.

[0230] In some embodiments, at least 40% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 41% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 42% of an anti- IL1R1 antibody exists as monomers in a formulation upon storage at 40°C for at least 2months. In some embodiments, at least 43% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 44% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 45% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 50% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 55% of an anti- IL1R1 antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 56% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 57% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 58% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 59% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 60% of an anti- IL1R1 antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 61% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 62% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 63% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 64% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 65% of an anti- IL1R1 antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 70% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 75% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 76% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 77% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 78% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 79% of an anti-ILlRl antibody exists as monomers in a formulationupon storage at 40°C for at least 2 months. In some embodiments, at least 80% of an anti- IL1R1 antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 85% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 86% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 87% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 88% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 89% of an anti- IL1R1 antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 90% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 91% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 92% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 93% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 94% of an anti- IL1R1 antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 95% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 96% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 97% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 98% of an anti-ILlRl antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, at least 99% of an anti- IL1R1 antibody exists as monomers in a formulation upon storage at 40°C for at least 2 months. In some embodiments, a formulation comprising an anti-ILlRl antibody does not gel upon storage at 40°C for at least 2 months.

[0231] In some embodiments, the amount of monomer in a formulation decreases less than 55%, 50%, 45%, 40%, 38%, 35% 30%, 25%, 20%, 15%, 10% , 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.2% or 0.1% upon storage at 5°C for more than 2 weeks, more than 4 weeks, more than 6 weeks, more than 2 months, more than 3 months, more than 4 months, more than 6 months, more than 8 months, more than 10 months, or more than 12 months. In someembodiments, upon storage at 5°C for 4 weeks, the amount of monomer in the formulation does not substantially decrease. In some embodiments, upon storage at 5°C for 4 weeks, the amount of monomer in the formulation decreases less than 5%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of monomer in the formulation decreases less than 4%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of monomer in the formulation decreases less than 3%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of monomer in the formulation decreases less than 2%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of monomer in the formulation decreases less than 1.5%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of monomer in the formulation decreases less than 1.0%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of monomer in the formulation decreases less than 0.8%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of monomer in the formulation decreases less than 0.6%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of monomer in the formulation decreases less than 0.5%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of monomer in the formulation decreases less than 0.4%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of monomer in the formulation decreases less than 0.3%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of monomer in the formulation decreases less than 0.2%. In some embodiments, upon storage at 5°C for 4 weeks, the amount of monomer in the formulation decreases less than 0.1%.

[0232] In some embodiments, upon storage at 5°C for 2 months, the amount of monomer in the formulation decreases less than 5%. In some embodiments, upon storage at 5°C for 2 months, the amount of monomer in the formulation decreases less than 4%. In some embodiments, upon storage at 5°C for 2 months, the amount of monomer in the formulation decreases less than 3%. In some embodiments, upon storage at 5°C for 2 months, the amount of monomer in the formulation decreases less than 2%. In some embodiments, upon storage at 5°C for 2 months, the amount of monomer in the formulation decreases less than 1.5%. In some embodiments, upon storage at 5°C for 2 months, the amount of monomer in the formulation decreases less than 1.0%. In some embodiments, upon storage at 5°C for 2 months, the amount of monomer in the formulation decreases less than 0.8%. In some embodiments, upon storage at 5°C for 2 months, the amount of monomer in the formulation decreases less than 0.6%. In some embodiments, upon storage at 5°C for 2 months, the amount of monomer in the formulation decreases less than 0.5%. In someembodiments, upon storage at 5°C for 2 months, the amount of monomer in the formulation decreases less than 0.4%. In some embodiments, upon storage at 5°C for 2 months, the amount of monomer in the formulation decreases less than 0.3%. In some embodiments, upon storage at 5°C for 2 months, the amount of monomer in the formulation decreases less than 0.2%. In some embodiments, upon storage at 5°C for 2 months, the amount of monomer in the formulation decreases less than 0.1%.

[0233] In some embodiments, the amount of monomer in a formulation decreases less than 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.2% or 0.1% upon storage at 25°C for more than 2 weeks, more than 4 weeks, more than 6 weeks, more than 2 months, more than 3 months, more than 4 months, more than 6 months, more than 8 months, more than 10 months, or more than 12 months. In some embodiments, upon storage at 25°C for 4 weeks, the amount of monomer in the formulation does not substantially increase. In some embodiments, upon storage at 25°C for 4 weeks, the amount of monomer in the formulation decreases less than 5%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of monomer in the formulation decreases less than 4%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of monomer in the formulation decreases less than 3%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of monomer in the formulation decreases less than 2%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of monomer in the formulation decreases less than 1.5%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of monomer in the formulation decreases less than 1.0%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of monomer in the formulation decreases less than 0.8%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of monomer in the formulation decreases less than 0.6%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of monomer in the formulation decreases less than 0.5%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of monomer in the formulation decreases less than 0.4%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of monomer in the formulation decreases less than 0.3%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of monomer in the formulation decreases less than 0.2%. In some embodiments, upon storage at 25°C for 4 weeks, the amount of monomer in the formulation decreases less than 0.1%.

[0234] In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 5%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 4%. Insome embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 3%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 2%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 1.9%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 1.8%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 1.7%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 1.6%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 1.5%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 1.4%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 1.3%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 1.2%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 1.1%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 1.0%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 0.9%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 0.8%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 0.7%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 0.6%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 0.5%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 0.4%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 0.3%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 0.2%. In some embodiments, upon storage at 25°C for 2 months, the amount of monomer in the formulation decreases less than 0.1%.

[0235] In some embodiments, the amount of monomer in a formulation decreases less than 50%, 45%, 40%, 38%, 35% 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1%, or 0.5% upon storage at 40°C for more than 2 weeks, more than 4 weeks, more than 6 weeks, morethan 2 months, more than 3 months, more than 4 months, more than 6 months, more than 8 months, more than 10 months, or more than 12 months. In some embodiments, upon storage at 40°C for 4 weeks, the amount of monomer in the formulation decreases less than 50%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of monomer in the formulation decreases less than 45%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of monomer in the formulation decreases less than 40%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of monomer in the formulation decreases less than 38%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of monomer in the formulation decreases less than 35%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of monomer in the formulation decreases less than 30%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of monomer in the formulation decreases less than 25%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of monomer in the formulation decreases less than 20%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of monomer in the formulation decreases less than 15%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of monomer in the formulation decreases less than 14%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of monomer in the formulation decreases less than 13%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of monomer in the formulation decreases less than 12%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of monomer in the formulation decreases less than 11%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of monomer in the formulation decreases less than 10%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of monomer in the formulation decreases less than 9%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of monomer in the formulation decreases less than 8%. In some embodiments, upon storage at 40°C for 4 weeks, the amount of monomer in the formulation dec...

Claims

1. CLAIMS1. A stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises less than 130 mM arginine and a pH of 4.4 - 6.5, wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), aHCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT), and wherein the anti-ILlRl antibody is present at a concentration of greater than 80 mg / ml.

2. The stable formulation of claim 1, wherein the anti-ILlRl antibody has a pl of 7.4 to 7.8.

3. The stable formulation of claim 2, wherein the anti-ILlRl antibody has a pl of 7.6.

4. The stable formulation of any one of the preceding claims, wherein the formulation comprises a buffer.

5. The stable formulation of claim 4, wherein the buffer is acetate, succinate or histidine.

6. The stable formulation of claim 4 or 5, wherein the buffer is present at a concentration of 15 mM to 75mM.

7. The stable formulation of claim 5 or 6, wherein the buffer comprises 25-50 mM acetate.

8. The stable formulation of claim 5 or 6, wherein the buffer comprises 25-50 mM succinate.

9. The stable formulation of claim 5 or 6, wherein the buffer comprises 25-50 mM histidine.

10. The stable formulation of any one of preceding claims, wherein the pH is 4.5 - 5.5.

11. The stable formulation of any one of claims 1-9, wherein the pH is 4.4 - 5.7.

12. The stable formulation of any one of claims 1-9, wherein the pH is 4.4 - 5.4.

13. The stable formulation of any one of claims 1-9, wherein the pH is 4.7 - 5.1.

14. The stable formulation of any one of claims 1-9, wherein the pH is 4.7 - 5.7.

15. The stable formulation of any one of claims 1-9, wherein the pH is 5.0 - 5.4.

16. The stable formulation of any one of claims 1-9, wherein the pH is 5.0 - 6.1.

17. The stable formulation of any one of the preceding claims, wherein the pH is 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.2, 5.3, 5.4, 5.6, 5.7, 5.8, 5.9, 6.0 or 6.1.

18. The stable formulation of any one of preceding claims, wherein the formulation comprises less than 120 mM, 100 mM, 80 mM, 60 mM, 50 mM, 30 mM arginine.

19. The stable formulation of any one of preceding claims, wherein the formulation comprises 75 mM arginine.

20. The stable formulation of any one of claims 1-18, wherein the formulation comprises 67 mM arginine.

21. The stable formulation of claim 18, wherein the formulation is substantially free of arginine.

22. The stable formulation of any one of preceding claims, wherein the formulation comprises a sugar.

23. The stable formulation of claim 22, wherein the sugar is a trehalose, sucrose, lactose, mannitol, mellibiose, melezitose, raffinose, mannotriose, or stachyose.

24. The stable formulation of claim 22 or 23, wherein the formulation comprises 1-15% (w / v) sugar.

25. The stable formulation of claim 24, wherein the formulation comprises 7% (w / v) sugar.

26. The stable formulation of any one of preceding claims, wherein the formulation comprises a surfactant.

27. The stable formulation of claim 26, wherein the surfactant is polysorbate-20 or polysorbate-80.

28. The stable formulation of claim 26 or 27, wherein the surfactant is present in the formulation at a concentration from about 0.001% (w / v) to about 0.05% (w / v).

29. The stable formulation of any one of the preceding claims wherein the formulation comprises salt.

30. The stable formulation of claim 29, wherein the salt is sodium chloride, or magnesium chloride.

31. The stable formulation of claim 29 or 30, wherein the salt is present at a concentration of 25-150 mM.

32. The stable formulation of claim 31, wherein the salt is present at a concentration of 100 mM.

33. The stable formulation of any one of preceding claims, wherein the formulation comprises an amino acid.

34. The stable formulation of claim 33, wherein the amino acid is a basic amino acid or an acidic amino acid.

35. The stable formulation of claim 33 or 34, wherein the amino acid is lysine, glutamate, or proline.

36. The stable formulation of claim 35, wherein the amino acid is present at a concentration of 25- 100 mM.

37. The formulation of claim 36, wherein the amino acid is present at a concentration of 75 mM.

38. A stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises 20-60 mM acetate, a basic amino acid, and pH of 4.2-5.7 wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT), and wherein the anti-ILlRl antibody is present at a concentration of greater than 80 mg / ml.

39. The stable formulation of claim 38, wherein the basic amino acid is present at a concentration of 50-100 mM.

40. The stable formulation of claim 38 or 39, wherein the formulation further comprises an acidic amino acid and / or proline.

41. The stable formulation of claim 40, wherein the acidic acid and / or proline is present at a concentration of 50-100 mM.

42. The stable formulation of claim 41, wherein the acidic acid and / or proline is present at a concentration of 75 mM.

43. The stable formulation of any one of claims 38-42, wherein the formulation comprises a sugar.

44. A stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises 20-60 mM acetate, a sugar, and a pH of 4.2-5.7, and wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), aHCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT), andwherein the anti-ILlRl antibody is present at a concentration of greater than 80 mg / ml.

45. The stable formulation of claim 44, wherein the formulation further comprises a basic amino acid, an acidic amino acid and / or proline.

46. The stable formulation of claim 45, wherein the basic amino acid, the acidic acid and / or proline is present at a concentration of 50-100 mM.

47. The stable formulation of claim 46, wherein the basic amino acid, the acidic acid and / or proline is present at a concentration of 75 mM.

48. The stable formulation of any one of claims 38-47, wherein the pH is 4.7 - 5.7.

49. The stable formulation of any one of claims 38-48, wherein the pH is 5.0 - 5.4.

50. The stable formulation of any one of claims 38-49, wherein the pH is 5.2.

51. The stable formulation of any one of claims 38-50, wherein the formulation comprises 5% w / v sugar.

52. The stable formulation of any one of claims 38-50, wherein the formulation comprises 7% w / v sugar.

53. The stable formulation of any one of claims 38-50, wherein the formulation comprises 8% w / v sugar.

54. A stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises 10-50 mM histidine, an amino acid, and a pH of 5.5-6.5, and wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT), and wherein the anti-ILlRl antibody is present at a concentration of greater than 80 mg / ml.

55. The stable formulation of claim 54, wherein the amino acid is present at a concentration of 50-100 mM.

56. The stable formulation of claim 54 or 55, wherein the amino acid is a basic amino acid, an acidic amino acid, proline or a combination thereof.

57. The stable formulation of claim 56, wherein the basic amino acid is present at a concentration of 75 mM.

58. The stable formulation of claim 56 or 57, wherein the acidic amino acid is present at a concentration of 75 mM.

59. The stable formulation of any one of claims 56-58, wherein the proline is present at a concentration of 75 mM.

60. The stable formulation of any one of claims 54-59, wherein the formulation comprises a sugar.

61. The stable formulation of any one of claims 54-60, wherein the formulation comprises a salt.

62. A stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises 10-50 mM histidine, a sugar, and a pH of 5.5-6.5, and wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), aHCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9(YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT), and wherein the anti-ILlRl antibody is present at a concentration of greater than 80 mg / ml.

63. The stable formulation of claim 62, wherein the formulation comprises a salt.

64. The stable formulation of claim 62 or 63, wherein the formulation further comprises a basic amino acid, an acidic amino acid and / or proline.

65. The stable formulation of claim 64, wherein the basic amino acid, the acidic acid and / or proline is present at a concentration of 50-100 mM.

66. The stable formulation of claim 65, wherein the basic amino acid, the acidic acid and / or proline is present at a concentration of 75 mM.

67. The stable formulation of any one of claims 54-66, wherein the pH is 6.1.

68. The stable formulation of any one of claims 62-67, wherein the formulation comprises 2- 10% w / v sugar.

69. The stable formulation of any one of claims 62-68, wherein the formulation comprises 5% w / v sugar.

70. The stable formulation of any one of claims 62-68, wherein the formulation comprises 8% w / v sugar.

71. A stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises 25-75 mM succinate, a basic amino acid, and a pH of5.0-6.0, and wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT), and wherein the anti-ILlRl antibody is present at a concentration of greater than 80 mg / ml.

72. A stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises 25-75 mM succinate, a salt, and a pH of 5.0-6.0, and wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), aHCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT), and wherein the anti-ILlRl antibody is present at a concentration of greater than 80 mg / ml.

73. The stable formulation of claim 72, wherein the formulation comprises a basic amino acid.

74. The stable formulation of claim of 73, wherein the basic amino acid is present at a concentration of 50-100 mM.

75. The stable formulation of claim 74, wherein the basic amino acid is present at a concentration of 75 mM.

76. The stable formulation of any one of claims 71-75, wherein the formulation further comprises an acidic amino acid and / or proline.

77. The stable formulation of claim 76, wherein the acidic acid and / or proline is present at a concentration of 50-100 mM.

78. The stable formulation of claim 77, wherein the acidic acid and / or proline is present at a concentration of 75 mM.

79. The stable formulation of any one of claims 71-78, wherein the formulation comprises a sugar.

80. A stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises 20-60 mM succinate, a sugar, and a pH of 5.0-6.0, and wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), aHCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9(YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT), and wherein the anti-ILlRl antibody is present at a concentration of greater than 80 mg / ml.

81. The stable formulation of claim 80, wherein the formulation further comprises a basic amino acid, an acidic amino acid and / or proline.

82. The stable formulation of claim 81, wherein the basic amino acid, the acidic acid and / or proline is present at a concentration of 50-100 mM.

83. The stable formulation of claim 82, wherein the basic amino acid, the acidic acid and / or proline is present at a concentration of 75 mM.

84. The stable formulation of any one of claims 71-83, wherein the pH is 5.6.

85. The stable formulation of any one of claims 71-84, wherein the formulation comprises 2- 10% w / v sugar.

86. The stable formulation of any one of claims 85, wherein the formulation comprises 5% w / v sugar.

87. The stable formulation of any one of claims 34-86, wherein the basic amino acid is lysine or arginine.

88. The stable formulation of any one of claims 34-87, wherein the acidic amino acid is glutamate.

89. The stable formulation of claim 87, wherein arginine is present in the formulation at a concentration of less than 130 mM.

90. The stable formulation of claim 89, wherein arginine is present at a concentration of < 75 mM.

91. The stable formulation of any one of claims 38-90, wherein the sugar is sucrose.

92. The stable formulation of any one of claims 38-91, wherein the formulation comprises a salt.

93. The stable formulation of claim 92, wherein the salt is magnesium chloride or sodium chloride.

94. The stable formulation of claim 91 or 92, wherein the formulation comprises 50-100 mM salt.

95. The stable formulation of claim 94, wherein the formulation comprises 75 mM salt.

96. The stable formulation of any one of the preceding claims, wherein formulation comprises 80-200 mg / ml of the anti-ILlRl antibody.

97. The stable formulation of claim 96, wherein formulation comprises 100-150 mg / ml of the anti-ILlRl antibody.

98. The stable formulation of claim 96, wherein the formulation comprises 135 mg / ml - 165 mg / ml the anti-ILlRl antibody.

99. The stable formulation of claim 96, wherein the formulation comprises 145 mg / ml - 160 mg / ml the anti-ILlRl antibody.

100. The stable formulation of claim 97, wherein formulation comprises 100 mg / ml of the anti-ILlRl antibody.

101. The stable formulation of any one of claims 96-99, wherein formulation comprises 150 mg / ml of the anti-ILlRl antibody.

102. A stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises:(i) 150 mg / mL anti-ILlRl antibody,(ii) 25 mM sodium acetate,(iii) a pH of 5.2,(iv) 7% w / v sucrose, and(v) 0.02% w / v polysorbate 20, and wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT).

103. A stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises:(i) 150 mg / mL anti-ILlRl antibody,(ii) 25 mM sodium acetate,(iii) a pH of 4.5-5.7,(iv) 7% w / v sucrose, and(v) 0.02% w / v polysorbate 20, and wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT).

104. The stable formulation of claim 103, wherein the pH is 4.5 - 5.0.

105. The stable formulation of claim 103, wherein the pH is 4.7 - 5.7.

106. The stable formulation of claim 103, wherein the pH is 5.0 - 5.4.

107. The stable formulation of any one of claims 103-106, wherein the pH is 5.0.

108. The stable formulation of any one of claims 103-106, wherein the pH is 4.5.

109. A stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises:(i) 150 mg / mL anti-ILlRl antibody,(ii) 25 mM sodium acetate,(iii) a pH of 4.4 - 5.4,(iv) 25.9 mg / ml proline, and(v) 0.02% w / v polysorbate 20, and wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 of SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT).

110. The stable formulation of claim 109, wherein the pH is 4.6 - 5.2.

111. The stable formulation of claim 109, wherein the pH is 4.7 - 5.1.

112. The stable formulation of any one of claims 109-111, wherein the pH is 4.9.

113. The stable formulation of any one of claims 109-111, wherein the pH is 5.0.

114. A stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises:(i) 150 mg / mL anti-ILlRl antibody,(ii) 25 mM sodium acetate,(iii) a pH 4.9,(iv) 25.9 mg / ml proline, and(v) 0.02% w / v polysorbate 20, and wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 of SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT).

115. A stable formulation comprising an anti-interleukin- 1 receptor 1 (IL1R1) antibody, wherein the formulation comprises:(i) 150 mg / mL anti-ILlRl antibody,(ii) 25 mM sodium acetate,(iii) a pH 5.0,(iv) 66.5 mM arginine, and(v) 3.5 % w / v sucrose(vi) 0.02 % w / v polysorbate 20, and wherein the anti-ILlRl antibody comprises a HCDR1 of SEQ ID NO: 5 (FHWIA), a HCDR2 or SEQ ID NO: 6 (IIHPGASDTRYSPSFQG), a HCDR3 of SEQ ID NO: 7 (QRELDYFDY), a LCDR1 of SEQ ID NO: 8 (RASQSIGSSLH), a LCDR2 of SEQ ID NO: 9 (YASQSFS), and a LCDR3 of SEQ ID NO: 10 (HQSSSLPLT).

116. The stable formulation of any one of the preceding claims, wherein the anti-ILlRl antibody comprises a variable heavy chain (VH) of SEQ ID NO: 3 and a variable light chain (VL) of SEQ ID NO: 4.

117. The stable formulation of any one of the preceding claims, wherein the anti-ILlRl antibody comprises a IgG2 Fc region.

118. The stable formulation of any one of the preceding claims, wherein the anti-ILlRl antibody comprises a heavy chain of SEQ ID NO: 1 and a light chain of SEQ ID NO: 2.

119. The stable formulation of any one of the preceding claims, wherein at least the 95% of the anti-ILlRl antibody exists as a monomer after 3 rounds of freeze and thaw cycles.

120. The stable formulation of any one of the preceding claims, wherein at least the 99% of the anti-ILlRl antibody exists as a monomer after 3 rounds of freeze and thaw cycles.

121. The formulation of any one of the preceding claims, wherein the amount of HMW species in the formulation increases less than 0.2 % after 3 rounds of freeze and thaw cycles.

122. The formulation of any one of the preceding claims, wherein the amount of HMW species in the formulation increases less than 0.3% after 6 rounds of freeze and thaw cycles.

123. The stable formulation of any one of the preceding claims, wherein the amount of HMW species in the formulation increases less than 1.4%, less than 1.2%, less than 1%, or less than 0.8% upon storage at 25° C for 4 weeks.

124. The stable formulation of any one of the preceding claims, wherein the amount of HMW species in the formulation increases less than 1%, less than 0.8%, less than 0.6%, or less than 0.5% upon storage at 5° C. for 4 weeks.

125. The stable formulation of any one of the preceding claims, wherein the amount of HMW species in the formulation increases less than 50%, less than 38%, less than 30%, less than 15%, less than 10 %, or less than 8 % upon storage at 40° C. for 4 weeks.

126. The stable formulation of any one of the preceding claims, wherein the amount of fragments in the formulation increases less than 5%, less than 3%, less than 2% or less than 1 % upon storage at 40° C. for 4 weeks.

127. The stable formulation of any one of the preceding claims, wherein the amount of fragments in the formulation increases 0.5% or less, 0.2% or less, or 0.1% or less, upon storage at 5° C or 25° C. for 4 weeks.

128. The stable formulation of any one of the preceding claims, wherein the amount of acidic species in the formulation increases less than 1%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1% upon storage at 5° C for 4 weeks.

129. The stable formulation of claim 128, wherein the amount of acidic species in the formulation does not substantially increase upon storage at 5° C for 4 weeks.

130. The stable formulation of any one of the preceding claims, wherein the amount of acidic species in the formulation increases less than 1%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1% upon storage at 25° C for 4 weeks.

131. The stable formulation of claim 130, wherein the amount of acidic species in the formulation does not substantially increase upon storage at 25° C for 4 weeks.

132. The stable formulation of any one of the preceding claims, wherein the amount of acidic species in the formulation increases less than 30%, less than 26%, less than 10%, less than 8%, or less than 7% upon storage at 40° C for 4 weeks.

133. The stable formulation of any one of the preceding claims, wherein the formulation has a viscosity of less than 25 cp at 20° C.

134. The stable formulation of any one of the preceding claims, wherein the formulation has a viscosity 15 cp or less at 20° C.

Images